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ABSTRACT   Title : A Randomized Prospective Open Label Comparative Study Of 
Olopatadine With Sodium Cromoglycate In Allergic Conjunctivitis 
 Background: 
Allergic conjunctivitis is the second most common cause of ocular 
morbidity in India and it accounts about20% of cases attending ophthalmology 
clinics. Ocular itching and nasal symptoms adversely affect the quality of life 
of patients. 
Aim 
To compare the efficacy and tolerability of  0.2%  olopatadine 
hydrochloride once daily with 2% sodium cromoglycate four times daily  in 
allergic conjunctivitis 
Materials  and Method 
After obtaining written informed consent, 120 patients who satisfy the 
eligibility criteria  were enrolled into the study.  Participants were randomly 
allocated into 2 groups; one receiving olopatadine hydrochloride 0.2% 
ophthalmic solution OD and the other sodium cromoglycate 2% ophthalmic 
solution QID for 4 weeks. Patient’s ocular signs and symptoms assessment 
were done  by a 4-point scale at the end of 2nd, 3rd  and 4th week. Adverse 
events, if any will be noted during the study and patients will be followed up to 
two weeks. 
Results : 
Change from baseline itching score were 2.5 in olopatadine group 
compared to 2.2 in sodium cromoglycate group( P value-0.006) during 4th 
week. Change from baseline redness score were 2.36 in olopatadine group 
compared to sodium cromoglycate group is 1.96( P value0.002) during 4th 
week. Both treatments show reduction of  signs and  symptoms  scores( p 
value<0.001). No treatment related adverse effects noted during study. 
Conclusion : 
Both 0.2%olopatadine and 2% sodium cromoglycate are effective in 
treating allergic conjunctivitis. 0.2%olopatadine once daily shows better 
reduction of itching and redness score during 4th week than 2% sodium 
cromoglycate. Both drugs are safe and well tolerated. 
Key Words: Olopatadine, Sodium Cromoglycate. Allergic Conjunctivitis. 
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INTRODUCTION 
 Allergic diseases are the fifth leading diseases among chronic diseases 
in the world. It affects about 40% percentage of entire population(1).There is a 
worldwide increase in Allergic diseases over the last ten years (2).The 
prevalence of allergic diseases among school children is gradually increasing 
and varies from 0.3% to 20.5%. A single cause for allergic disease cannot be 
pointed out and  we should  consider a contribution of many factors like 
genetics, air  pollution in urban areas, pets and early childhood exposure for 
this increase(2) . 
Ocular allergy is one of the most common type of allergy .Ocular 
allergy accounts for 15%-20% of population all over. It is common among 
school going children and adolescent age group. It is usually associated with 
other allergic diseases. They are having great impact on our day to day 
activities(3). 
The term allergic conjunctivitis includes seasonal allergic conjunctivitis 
(SAC), perennial allergic conjunctivitis (PAC), vernal kerato conjunctivitis 
(VKC), and atopic kerato conjuntivitis (AKC).However the clinical and 
pathophysiological features of AKC and VKC are quite different from SAC 
and PAC, in spite of common allergy markers. The use of contact lenses or 
ocular prosthesis are associated with  giant papillary conjunctivitis (GPC) 
which is  often included in the group of ocular allergy, however they should not 
be considered as real allergic diseases(4). 
The most common form of ocular allergy is SAC, which represents 
about 90% of cases (3). The most prevalent allergens for SAC are grass, tree, 
weed pollen and outdoor molds. Although the signs and symptoms of SAC 
usually mild, it can hinder school performance, everyday activities, like  
reading, sleeping etc which  results  in overall reduction in the quality of 
life(2).  Allergic conjunctivitis is a type I hypersensitivity reaction mediated by 
IgE.The pathophysiology of  allergic conjunctivitis starts with an intial antigen 
sensitization,followed by mast cell activation, release of  histamine, 
tryptase,synthesis of prostaglandins and leukotreines.In the later phase, there is 
activation of eosinophils ,basophils, T cells,macrophages and neutrophils 
leading to a chronic stage of the disease(1). 
The treatment and management goals of allergic conjunctivitis are to 
minimize the inflammatory cascade associated with allergic response in the 
early stages of the pathological mechanism. It is noted that activation of 
histamine receptors on immune and non immune cells are associated with 
allergen-induced inflammation of the conjunctiva and its 
associated ocular allergic manifestations, including itching, edema, hyperemia 
and tearing(5).The treatment of allergic conjunctivitis depends on severity and 
chronicity(4). Non specific treatment measures like cold compression, artificial 
tears and avoidance of allergens is helpful to alleviate symptoms. The 
medications which are available for the treatment of allergic conjunctivitis 
belongs to different classes. 
  
Table 1.1 : Medications for Allergic Conjunctivitis(4) 
Types of Medications Examples 
H1 Receptor Antagonist 
 
Levocabastine 
Emedastine, 
Bepostatine,  
Alcaftadine 
 
 
Mast Cell Stabilizers Commonly Sodium 
Lodoxamide  
Pemirolast 
Nedocromil Sodium 
 
Antihistamines With Mast Cell-
Stabilizing Property. 
Ketotifen 
Fumarate, 
Azelastine 
Olopatadine. 
 
Topical NSAIDS Ketorolac 
Vasoconstrictors, Naphazoline 
Pheniramine 
Topical Steroids Prednisolone, 
Hydrocortisone 
Loteprednol, 
Fluorometholone, 
Oral Antihistamines, Fexofenadine 
Loratadine 
Cetirizine 
Olopatadine is a H1 selective antagonist with a mast cell stabilizing 
property, along with suppressing action on TNF α, IL-6 and IL-8 release. It is a 
well tolerated drug which gives rapid and long duration of relief from signs and 
symptoms of allergic conjunctivitis.(6) 
Sodium cromoglycate is a mast cell stabilizer. Studies shows  that  
sodium cromoglycate selectively and  rapidly phosphorylate proteins in mast 
cell membrane which is responsible for stopping the secretion and  mast cell  
re-stabilization after degranulation(7) . 
Recently Olopatadine hydrochloride 0.2% ophthalmic solution is  
approved  to be  given as single daily dosage for allergic conjunctivitis. Few 
studies were done in allergic conjunctivitis comparing efficacy and tolerability 
of 0.1% olapatadine and sodium cromoglycate 2% in India. In Tamil Nadu, not 
much studies have been done on allergic conjunctivitis.In this study we are  
going to compare the efficacy and tolerability of olopatadine 0.2% ophthalmic 
solution administered OD with sodium cromoglycate 2% ophthalmic solution 
administered QID in allergic conjunctivitis patients of Chengalpattu  
government hospital for 6 weeks duration. 
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REVIEW OF LITERATURE 
Ocular allergy is considered to be a Cinderella in allergic diseases. In 
clinical practice allergic conjunctivitis is most common cause of red eye. About  
10% of ophthalmological clinical consultation around the world is for ocular 
allergy(8).It is showing a great increase in incidence of ocular allergy during 
last decades. This  increase in incidence of ocular allergic conditions are 
mainly accountable  to climatic change, increased  pollution, pollen loads and  
patient’s increased sensitivity for immunological response to these 
environmental changes. The mast cells are present in large amount in 
conjunctiva, which makes it a best and preferred area for immediate 
hypersensitivity reactions. Severity of Allergic conjunctivitis ranges from mild 
form to severe form(9). 
       History  
 Various  milestones in history of allergic conjunctivitis and immunology helps 
in better understanding of immunological process and treatment of 
allergy(10).It was in 1819 London physician John Bostock  describes his own 
case of summer catarrah in his publication “ a case of periodical affection of 
the eyes and chest”(11).For the first time conjunctival provocation test was 
reported in the work by Charles Blackley  entitled  “Experimental Researches 
On The Causes And Nature Of Catarrhus Aestivus” published on 1873(10) 
.The description of allergic disease as a type I hypersensitivity was done by 
Coombs “and Gell in 1970(10).Later the mast cell preference in ocular tissue 
was shown in studies of Mathea Allansmith(10). The relevance of  role of eyes 
in the study of autoimmune disorders was defined by Author Silverstein in his 
work “ocular immunology on the birth of the new discipline”in1991(10). 
Definition 
The term ocular allergy include a group of conditions like seasonal  
allergic conjunctivitis(SAC), perennial allergic conjunctivitis(PAC), vernal 
keratoconjuntivitis(VKC),atopic kerato conjunctivitis(AKC) and giant papillary 
conjunctivitis(GPC)(12). Among these SAC and PAC are most common and 
self limiting  without any ocular surface damage(9).SAC and PAC are having 
some differences from VKC and AKC even though all are having common 
allergic markers.VKC and AKC affect cornea resulting  in corneal ulcers and 
scaring which may even lead to vision loss.(12) Giant papillary conjunctivitis is 
not a real allergic disease .But they are  included in  ocular allergy (12).  
Classification of Ocular Allergy 
       I. Based on Onset of Disease 
       Acute Form 
1. Seasonal Allergic Conjunctivitis 
2. Perennial Allergic Conjunctivitis 
Chronic form 
1. Vernal Keratoconjunctivitis  
2. Atopic Kerato Conjunctivitis 
3. Giant Papillary Conjunctivitis 
4. Contact Dermo conjunctivitis 
II. Based on signs and symptoms (13) 
1. Mild 
2. Moderate 
3. Severe 
III. Based on duration of episodes activity (14) 
Allergic Conjunctivitis classified into 
1. Quiescent 
2. Intermittent 
3. Persistent 
 
 
Fig. 2.1 : Classification of allergic conjunctivitis.(15) 
 
 
Table 2.1 : Clinical and Immunopathological Classification of 
Ocular Allergy(9) 
 
TYPE OF ALLERGIC 
CONJUNCTIVITIS IgE Mediated 
IgEand Non -IgE 
Mediated 
Non –IgE 
Mediated 
Intermittent SAC   
Persistent PAC VKC GPC 
Chronic  AKC CDC 
 
 
Etiology 
  The factors affecting ocular allergy are genetics, air pollution, urban 
areas, pets and early childhood exposure.(12) .The main cause of SAC is air-
born pollens from grasses,trees,rag weeds etc.SAC clinically presents more 
during spring and summer and less during winter season. Perennial allergic 
conjunctivitis can occur any time throughout the year, usually with allergens 
like animal dander, molds and dust mites.(16) 
Immunopathogenesis  
Allergic conjunctivitis is a IgE mediated type 1 hypersensitivity 
reaction. (16) The pathophysiology of allergic conjunctivitis have two stages 
When a  person comes in contact with allergen for the first time  there is an 
activation of immune response predominantly Th2 immune response and 
production of IgE antibodies. This is sensitization phase reaction. 
 
Fig:2.2 Time Course of Selected Inflammatory Mediators.(17) 
 
Fig: 2.3 Etiopathogenesis Of Corneal Epithelial damage.(18) 
In effecter phase reaction an already sensitized person comes in contact 
with allergen for the second time, there is an activation of effecter mechanism 
leading to degranulation of mast cells, releasing the contents into the 
surrounding area. This early response lasts for 20-30 minutes .(12) The 
released histamine will initiate a cascade of reactions. The release of many 
chemical mediators will cause vasodilatation, raised capillary permeability and 
increased mucous production .The chemical mediators like histamine, tryptase, 
kinnogenase, esinophil chemotactic factor of anaphylaxis (ECF-A) will be 
released. About 6-72 hours after exposure to allergens, late phase of response 
begin. This phase of reaction will involve eosinophils, basophils, T cells, 
macrophages and neutrophils infiltrating into the conjunctiva. The chemical 
mediators released during  late phase period are leukotriene B4, leukatreine C4, 
leukotreine D4, prostaglandins, platelet activation factor.   
The histamine released during mast cell degranulation is mainly 
responsible for symptoms of allergic conjunctivitis like itching, redness etc 
.Recently in a mouse model leukotriene B4 was recognized to be a mediator of 
itching(19). Like mast cells basophils also play an important role in allergic 
inflammation. Esinophil will secrete cytokines and cytotoxic proteins which 
will cause structural damage and fibrosis.T cells play an important role in 
severe and chronic allergic eye conditions(20).Tryptase are involved in 
inflammatory cell infiltration of conjunctiva and extra cellular matrix 
degradation. The presence of tryptase in tears is regarded as biomarker for IgE 
mediated allergic eye conditions(21).  
  
 
Fig:2.4 Inflammatory Cascade  In Allergic Conjunctivitis (17) 
In VKC and AKC there is type I and T cell mediated type IV 
hypersensitivity reaction. Alterations in MMP and tissue inhibitors of MMP   
responsible for excessive extracellular matrix deposition and papillae formation 
in VKC. In chronic  ocular allergy fibroblast will induce pro-inflammatory 
mediators like chemokines and adhesion molecules which are responsible for 
corneal lesion(19) 
Clinical Features 
The symptoms and signs of acute form of allergic conjunctivitis are 
Symptoms 
1. Itching 
2. Watering 
3. Foreign  body sensation 
4. Photophobia 
5. Discharge 
6. Blurring of vision 
 7.Discomfort 
Signs 
1. Redness 
2. Chemosis 
3. Eyelid edema 
Types of Allergic Conjunctivitis  
Seasonal and Perennial allergic Conjunctivitis 
  SAC and PAC are two forms of allergic conjunctivitis disease affecting 
both eyes. They presents with itching, redness, watering blurring of vision, 
photophobia, gritty sensation of eyes. They have  self limiting character. 
Symptoms and signs of SAC depend on types of exposed allergens.The 
incidence of SAC s more during August to September which  is mainly related 
of outdoor molds. It is  mainly related to tree pollens during spring season. It 
has got association with allergic rhinitis and bronchial asthma.  
Eyes in Allergic Conjunctivitis 
 
 
 
Perennial conjunctivitis (PAC) is another form of AC usually induced 
by exposure to dust mites,fungi, animal epithelial or occupational allergy(22). 
PAC patients have symptoms all throughout the year. It has no age or sex  
prediliction.PAC are common  in patients  with allergic rhinitis and other  
allergic diseases .The swabs from conjunctiva of these patients  shows more 
eosinophil count. Co-morbidities like dry eyes are seen in PAC patients 
because of prolonged disease duration. 
Atopic Keratoconjunctivitis (AKC) 
It is a form of allergic conjunctivitis with chronic course which is 
common among males. Majority of AKC patients have concomitant 
associationwith eczema or bronchial asthma .The AKC patients usually present 
as allergic shiners. The clinical symptoms of AKC are intense itching, burning, 
photophobia, tearing, blurring of vision and discharge of eyes of both sides.  
Periorbital eczema, lid edema, conjunctival chemosis are  the other common 
clinical signs of AKC. Papillary hypertrophy is seen with both upper and lower 
tarsal conjunctival hyperplasia and the limbal nodules may be present with or 
without Horner-Trantas dots. Horner-Trantas dots are collection of degenerated 
cellular debris and eosinophils. In severe condition of AKC  ,the scaring and 
cicatrizing of conjunctivain severe forms of AKC  results in  formation of  
symblepharon , sub epithelial tissue fibrosis,and fornices shortening (23).  
 
 
Atopic conjunctivitis. Vernal Catarrah                                            
Histological examination of the conjunctival epitheliumof an AKC 
patient gives a picture of  mast cells,lymphocytes and eosinophils mixture.The 
T -cell is considered as a major triggering primer in both chronic AKC and 
VKC (23). As AKC are seen in immune compromised atopic patients, there is a 
chance for secondary infection which should be ruled out and treated early.(10) 
Vernal keratoconjunctivitis (VKC) 
   
       Vernal Conjunctivitis         Vernal conjunctivitis: corneal plaque 
 
Vernal conjunctivitis is a disease of both eyes with inflammation of 
conjunctiva. It is common during the spring and summer season (4).In VKC the 
children and adults having a history of seasonal allergy, bronchial asthma or 
eczema are commonly affected. VKC show a higher incidence in warm and 
temperate regions with chance of infection twice greater in boys compared to 
girls .VKC is commonly seen around the age of 11to 13 years. The disease in 
children are mild and self-limited where as in adults, it is a severe disease with 
indefinite recurrence. The most common symptom  is intense  pruritis along 
with other  symptoms likephotophobia, burning, watering, ptosis and  thick, 
ropy, yellowish mucoid discharge(4). 
The three varieties of the vernal conjunctivitis are palpebral, limbal and 
mixed type(24).In palpebral type of VKC the main sign is the cobblestone 
pattern of papillae on the superior tarsal conjunctiva.First there is a papillary 
hypertrophy after that there is hyperplasia and proliferation of substantia 
propria to form giant papillae. The pressure by cornea flattens the tops of the 
giant papillae leading to a patterned impression that resembles cobblestones. 
The presence of tiny group of vessels at the center of the papillae helps us to 
differentiate these follicles from those seen in trachoma patients. 
Chronic Atopic Conjunctivitis showing Cobblestone Papillae
A broad, thickened, gelatinous opacification of the superior limbus that 
can override the cornea is seen in the limbal variety of VKC. In limba
VKC, the tiny vessels appear around the sides of the elevations of follicles. 
Microscopically examination shows an infiltration of lymphocytes, 
macrophages, basophils, plasma cells and many eosinophils in tissues. An 
important feature in limbal v
dots. It is a white, chalk
which is located at the limbus. We can see that 50% of VKC cases have corneal 
involvement.It include superficial pannus and a
Small, gray patches of necrotizing epithelium may involve the upper one third 
to two thirds of the cornea 
with flour. Under fluorescent staining, vernal “shield ulcer” is se
shallow,non vascularized, indolent ulcer on the superior surface of cornea. The 
ulcer edges are composed of shaggy, dead epithelial cells,with superficial 
stromal infiltrates.After healing of ulcer, a mild corneal opacity will persist at 
the level of Bowman’s layer of cornea.
ariety of VKC is the presence of Horner
-like dot, filled with eosinophils and epithelial debris 
 punctate epithelial keratitis. 
– in severe cases, the cornea appears to be dusted 
en as an oval, 
 
 
 
l form of 
-Trantas 
Giant Papillary Conjunctivitis 
Giant papillary conjunctivitis (GPC) is a syndrome of inflammation of 
the upper palpebral conjunctiva seen in people with contact lens or ocular 
prostheses or  protruding ocular sutures for a  longer period of time(25,26).It is 
related  to contact lens users and frequently  seen in soft lens users than in rigid 
lens users (26).The soft lens wearers will develop symptoms in 8 months and 
hard lens wearers take 8 years for the same to develop.The symptoms of GPC 
appear before the signs of superior tarsal involvement. Conditions that favor 
the development of GPC in lens users include increased lens deposits, 
increased wearing time and extended number of years the lenses have been 
worn, larger diameter lenses and soft lenses 
 
Giant papillary conjunctivitis 
GPC patients  mainly complains of mild itching on removal of  contact 
lenses and  which is associated  with increased mucus on the lenses and in the 
nasal canthus on getting up in the morning.Other complains of patients are 
increased lens awareness, blurring of vision after removing contact  
lens,excessive lens movement leading to  contact lens intolerance. Signs of 
GPC include a generalized thickening and hyperemia of the superior pretarsal 
conjunctiva during the early stage and small papillae become elevated. 
The conjunctiva becomes opaque as a result of cellular infiltration.Both  
macro papillae (0.3–1.0 mm) and giant papillae (1.0–2.0 mm) can be 
formed(4).Trantas dots and gelatinous nodules are formed near the limbus(27). 
The histology of GPC shows irregular thickening of the conjunctival 
epithelium over the papillae, with epithelial downgrowth into the stroma.The 
epithelium and stroma show infiltration of lymphocytes, basophils, 
polymorphonuclear neutrophil leukocytes, plasma cells eosinophils and 
macrophages along with proliferation of fibroblast. The number of eosinophils 
and basophils infiltrating conjunctiva is lower compared to that of vernal 
conjunctivitis.GPC arise due to multiple factors. Patients always have 
environmental antigens adhere to the mucus and proteins that normally forms a 
coat on the surface of all types of  contact lenses(28).These antigens, which 
persist as deposits on the contact lenses, are forced to come into contact with 
the superior tarsal conjunctiva while blinking. Mechanical trauma remains as 
an important factor in the process of GPC pathogenesis and it develops in 
patients who have ocular prostheses and exposed suture ends. This repeated 
exposure to antigen combined with the trauma from contact lens wear to the 
upper tarsal conjunctiva  result in triggering of a type IV basophil 
hypersensitivity reaction in conjunctiva.This is similar to  cutaneous  basophil 
hypersensitivity reaction. Along with this reaction a type I IgE mediated 
immediate hypersensitivity reaction also occu
ContactDermatoConjunctivitis
Contact allergy of the eyelids and conjunctiva are common among 
patients in ophthalmology department. It is a  delayed type of cell
(type IV) hypersensitivity reaction in which Previous sensitization can have 
occur a little as 5 days or as long as years before
eye drops, cosmetics, cloths, jewelry, plastics, animal or vegetable products, 
and industrial chemicals.
with this reaction include gentamicin, idoxuridine, neomycin,  atropine, 
thimerosal, and penicillin.
allergic reactions. 
The reaction begins with intense itching and papillary conjunctivitis 
greatly affecting inferior palpebral co
discharge is seen along with it. The adjacent skin of the lower eye lids and 
rs. 
 
 
. The most common stimuli are 
12 The ocular drugs which are commonly associated 
13 Other preservatives can also produce similar 
njunctiva. A mucoid or mucopurulent 
-mediated 
lateral canthi show typical eczematous dermatitis involvement. Chronic use of 
the allergen  lead to keratinization of eye lid leading to punctal edema and 
stenosis. The cornea may show punctate epithelial keratitis and erosions on 
examination. Conjunctival scrapings show monocytes, polymorphonuclear 
neutrophil leukocytes, mucus and eosinophils. 
Diagnosis of Allergic Conjunctivitis 
The diagnosis of AC can be made from family history, personal history, 
history of atopy, clinical signs and symptoms, results of additional  appropriate 
tests (21). Patients may have clinical history of AC during any age. Rhinitis 
often accompany AC in 66% of adults population (20) about 97% among 
children group (29), asthma (in 16% of adults (30) and 56% of children (29), 
and with  atopic dermatitis in 25%-42% of adults (31) and 33% in children 
(29)). AC has conjunctival itching as its main symptom(32), watering and a 
stinging sensation. Photophobia and Blurring of vision can occur in  severe 
cases. Blurring of vision is because of change in composition and the tear film 
stability. It is present in more than 78% of patients and  measured with the help 
of  interferometry (33). 
The signs in AC pateints are examined using slit lamp biomicroscopy. 
When this is not possible, a light source along with fluorescein staining can be 
used. The defects in ocular epithelial cells is visualized using this technique. 
Mild to moderate redness and moderate conjunctival edema can be observed. 
The eyelids are mostly edematous, and the palpebral conjunctiva will have a 
pale pink in colour. In some AC patients, areas of mild papillary hypertrophy 
are seen in upper palpebral conjunctiva. Aqueous or mucoid type of discharge 
is seen. The cornea remains often  unaffected (34).AC is confirmed by skin 
tests with suspected allergens or serum specific IgE to various whole allergens 
or their purified forms (21).The main disadvantage is that these skin tests or 
specific IgE tests are  that the results not often conclusive.24% of AC patients 
are seemed to be sensitized to variety of allergens(35).Some AC patients show 
negative skin test even when there is no association with allergic rhinitis(36). 
Other methods which help in diagnosing AC are 
Tear fluid analysis 
The levels of free specific IgE, total IgE, cytokines,and markers of 
inflammation like eosinophil cationic proteins can be measured in tear fluid. 
Conjunctival cyto diagnosis 
It is used in research purposes, but  is not valuable in routine clinical 
practice(37). 
Responses to medication 
By observing response to drugs like topical antihistamines or mast cell 
stabilizers diagnosis of AC can be made(38). 
  
By performing a conjunctival challenge test. 
The conjunctival challenge test can be used to confirm the reactivity of 
allergen in the AC patient’s conjunctiva showing positive skin test results. The 
challenge test is very useful in 
 AC patients with negative skin tests.  
 Determining serum specific IgE level. 
 Assessing the local and specific responseof the conjunctiva in patients 
with history suggestive of AC. 
 In making diagnosis of patients who are sensitized to multiple allergens 
and  in cases of occupational allergy (39). 
COMORBIDITIES 
The co morbidities like dry eye disease and blepharitis should be ruled 
out.  
DIFFERENTIAL DIAGNOSIS 
Differential diagnosis of allergic conjunctivitis are: 
 Infectious conjunctivitis 
 Toxic conjunctivitis 
 Ocular rosacea 
 Keratitis 
 Episcleritis/scleritis 
 Angle closure glaucoma 
 Phlectenular Conjunctivitis  
COMPLICATIONS(12) 
For allergic conjunctivitis complications are usually rare. The 
complications arise due to the presence of secondary infections. This may 
include  
a) Corneal scar 
b) Loss of vision 
c) Bacterial infections 
d) Sinusitis 
e) Recurrence 
2.2 Scoring of signs and symptoms of allergic conjunctivitis(6,13,42) 
Sign Symptom 
Sign Symptom Scoring of sign symptom of allergic conjunctivitis                                               Score 0-absent      1- mild      2-moderate               3- severe Redness  Absent Slightly dilated bloodvessels, pink in colour 
More apparent vessel dilatation,vessel colour is more intense,involves most of vessel bed 
Numerous and obvious dilated blood vessels, colour deep red 
Itching  Absent Occasional itching,without tendency toscratch or rub the eyes 
Frequentitching with tendency toscratch or rub the eyes 
Continuous itching, frequently rubbingthe eyes 
watering  Absent  Occasional, No complaints of discomfort. 
Frequent, patient felt as discomfort Persistentand frequently accompanied by swabbing of the eye Chemosis Absent  slight edema detectable only by slit lamp 
 diffuse edema visible in normal room light Ballooning of overall bulbar conjunctiva. 
Lid edema absent Slight swelling on palprebal conjunctiva. 
Diffuse swelling on palprebal conjunctiva. Bullous swelling on palprebal conjunctiva. 
 Photophobia Absent.  Occasionally photophobic Continuously photophobic Eye responds with blepharospasm on exposure to light Foreign Body Sensation absent Occasionally  feeling sandy Frequent gritty sensation Continuous gritty sensation  
 
2.3 Differential Diagnosis of Ocular Allergy.(40,41) 
Reference(41). 
  SAC PAC VKC AKC GPC CDC 
Personal/ 
family 
history 
of atopy 
Common Common constant Possible  Possible  Possible 
Age 
 
Children/adu
lt 
Children/adu
lt 
children Adult Adult/adolesce
nt 
Adult 
Gender 
 
No pre-
dilection 
Nopre-
deliction 
Male Male 
 
No pre-
dilection 
No pre-
dilection 
Season 
 
Spring perennial Perennial/spri
ng 
perennial     spring No 
Corneal 
involvement 
No no yes yes         no No 
Vision Minimal minimal mild severe    minimal Minimal 
Papillary 
hypertrophy 
No no 7-8mm limbal 
involved 
<1mm >1mm No 
Per ocular 
skin 
involvement 
Edema edema edema dermatitis     edema Dermatiti
s 
Exposure to 
topical drugs 
No No No No       No Yes 
Contact lens 
wearers 
No No No No      yes No 
IgE level Elevated elevated variable Grossly  
elevated 
    variable Variable 
Esinophil 
cells 
Frequent Very 
frequent 
characteristic characterist
ic 
Not frequent Not 
frequent 
Globlet cells Increased increased increased decreased variable Variable 
Skin test Positive positive Non specific positive variable Variable 
Other atopic 
disease 
Rhinitis, 
asthma 
Rhinitis, 
asthma 
variable Rhinitis 
Asthma 
Dermatitis 
variable Variable 
Response to 
anti allergic 
drugs 
Characteristi
c 
Characteristi
c 
low low variable No 
Response to 
corticosteroi
ds 
constant constant constant  constant constant Constant 
 
 
TREATMENT 
Pharmacological properties of decongestants 
DRUG GROUP AGENTS MECHANISM  OF ACTION SIDE EFFECTS COMMENTS Topical ocular decongestants Naphazoline Tetrahydrozoline Phenylephrine Ephedrine Brimonidine 
α1 adrenergic agonists  
Rebound hyperemia, conjunctivitis medicamentosa, follicular reaction, contraindicated in narrow angle glaucoma 
Only for redness or in conjunction with first generation antihistamine  preparations; Action last for   2 - 4 h only 
 
Drugs like Tetrahydrozoline for AC  patients  came to market as early 
from 1950s(43).Naphazoline an α1 agonist was introduced for treatment of 
ocular allergy in 1970.It is a vasoconstrictor acting on α1adrenergic receptor 
which continues to produce immediate vasoconstriction. This helps in 
decongestion of reddened eyes. When they are used alone it only reduces 
redness but as combination with anti histamines it reduces both itching and 
redness .(1,43).When topical α1 adrenergic agonists are used  in AC patients for 
long period, it causes down regulation of α1 adrenergic receptors producing  
tachyphylaxis and rebound redness on discontinuation of drugs(44). These 
drugs are contraindicated in narrow angle glaucoma and angle closure 
glaucoma patients (1).Brimonidine , a α2 agonist drug  in low-dose  and  
concentration is being tried in many studies of AC patients .It is in final stage 
of FDA approval for the treatment of ocular redness (1). 
  
Antihistamines 
Pharmacological properties of antihistamines 
DRUG GROUP AGENTS 
MECHANISM  OF ACTION 
SIDE     EFFECTS 
COMMENTS 
Topical antihistamines 
AntazolinePheniramine,LevocabastineEmedastine Competitive inhibitionof  histamine receptors 
Sedation, irritation, dry eye 
This group is taken over by dual actingdrugs 
 
Systemicantihistaminic drugs have little efficacy in 
allergicconjunctivitis .It cause drying of the ocular surface, so it should be used 
only in patients having concurrent rhinitis or sinusitis (45).  Histamine 
receptors are primary targets in treatment of ocular allergy since histamine 
signaling is the main reason for signs and symptoms(46).  H1 , H2 ,H3 and H4 
are the four histamine receptors involved in ocular allergy(1). H1 and H2 
receptors take part in pruritus, redness, and cytokine release, proliferation of 
fibroblast, adhesion molecule expression, vascular permeability and production 
of procollagens (1,47–49). H4 receptor is mainly involved in cytokine and 
chemokine release, chemotaxis and adhesion molecule expression (48). 
Topical antihistaminic drugs competitively and reversibly inhibit 
histamine receptors in conjunctiva (46,49). The symptomatic relief of drugs 
like antazoline and pheniramine are immediate and temporary. So it requires 
frequent dosing. First-generation antihistamines are lipid soluble and pass 
through blood brain barrier, causing central side effects such as sedation (50). 
The topical combination  of antihistamine--decongestant are available as OTC 
drugs owing to its good safety and experience profile among patients. The 
immediate relief shown in the pateints by these group of drugs are the main 
reason for their great acceptance (49,51) even though there is a mismatch in 
time of action between anti histamines and decongestants. Newer-generation 
topical antihistamines are more potent inhibitors of histamine stimulated 
cytokine synthesis in intact conjunctival epithelial cells (49). The second-
generation antihistamine levocabastine was the first drug to be used in isolation 
and had a longer duration of action than the first-generation agents. 
Levocabastine was also the first antihistamine shown to have multiple 
mechanisms of action in reducing  the early phase immune response and the 
late-phase response by reducing eosinophil activation and infiltration(49,52). 
Emedastine is second-generation anti-histamine that has a similar 
duration of action to levocabastine, but its superiority in prevention and 
treatment of allergic conjunctivitisis shown  in one of the prospective clinical 
trial (53). The second generation topical antihistamines having 4 h of duration 
of action  are given as four times daily dosing. Emedastine is approved for use 
in patients more than 3 years of age Emedastine shown to inhibit histamine 
evoked increased vascular permeability (49).  
 
 
Systemic Antihistamines 
Systemic antihistamine drugs are used only in restricted manner in 
treatment of ocular allergies. In many studies it is seen that ocular symptoms 
are more reduced effectively by topical antihistamines (54–56). Systemic 
antihistamines can increase dryness of eyes by decreasing tear production (57). 
The main issues with this group of drugs are sedation and cardio toxicity side 
effects even though they are less common (46). Systemic antihistamines are 
added to treatment when AC patients have other symptoms like rhinitis or 
generalized itching (46).  Newer antihistamines like bilastine show no sedating 
effect. They are very successful in treating  rhino conjunctivitis (58). 
Mast cell stabilizers 
Pharmacological properties of  mast cell stabilizers. 
DRUG GROUP AGENTS 
MECHANISM  OF ACTION 
SIDE EFFECTS COMMENTS 
Topical mast cellstabilizers 
Nedocromil sodiumPemirolastLodoxamide 
Inhibition of mast celldegranulation andrelease of histamine 
Burning sensation Headache. 
 
Commonly very weak activity;Lodoxamide perhaps most effective in VKC. 
 
Drugs like cromolyn (sodium cromoglycate), nedocromil sodium, 
pemirolast and lodoxamide belongs to this group. Cromolyn is the oldest drug 
in this group The mast cell stabilizers prevent degranulation of mast cells and 
prevent release of histamine and other mediators.It reduces the effects of both 
histamine and the influx of monocytes, eosinophils and neutrophils. But these 
ant allergic effects have been difficult to demonstrate in the eye 
clinically(59,60). Nedocromil sodium inhibits influx of chloride ion in mast 
cells, epithelial cells and neurons. Drugs like Pemirolast show inhibition of  
eosinophil chemotaxis along with  mast cell degranulation (60,61).But  in 
human conjunctival mast cells, cromolyn sodium failed to show  inhibition of  
histamine release and it was only marginally effective at very high 
concentrations (61).While drug  lodoxamide was much more potent than 
cromolyn which  block  eosinophil chemotaxis (61).Lodoxamide appears to be 
most efficacious for treating epitheliopathy and shield ulcers seen with 
VKC(1,62). The pemirolast  shows considerable clinical efficacy in SAC (1) 
Corticosteroids 
Pharmacological properties of corticosteroids. 
DRUG GROUP 
AGENTS 
MECHANISM  OF ACTION 
SIDE EFFECTS 
COMMENTS 
Topical corticosteroids 
ClobetasonebutyrateDexamethasone,Fluoromethalone,Hydrocortisone,Prednisolone,Rimexalone,Triamcinolone,Loteprendol 
Inhibition ofphospholipase Aresulting in inhibitionof PG andLeukotri
Increased intraocularpressure, cataractformation, delayedwound healing,headac
Should be used only for pulse therapyin chronic forms of 
ene synthesis. 
he, pharyngitis, rhinitis 
allergy (VKC,AKC, etc.) 
 
Glucocorticoids are effective therapy for various forms of allergic 
disease, ranging from allergic rhinitis to asthma, and including ocular allergy. 
Specifically, topical corticosteroids are highly effective in treating severe or 
chronic ocular allergy (63,64).This is because the corticosteroid acts on many 
steps of the allergic cascade, working on both molecular and cellular targets. 
The main mechanism of action of corticosteroid is inhibition of prostaglandin 
and leukotriene synthesis by arachidonic acid through blockage of 
phospholipase A (46).Corticosteroids works by inhibit proliferation and 
recruitment of mast cells (1,46,65–67). Steroids decrease the eosinophil 
production and induce apoptosis and phagocytic destruction of eosinophil 
(1,65–67).  The other effects of steroids include reducing the availability of 
histamine, both by increasing cellular stores and decreasing the expression of 
histamine receptors (67).  
Side effects  
 Immunosuppression 
 Superinfection 
 Cataract Formation 
 Corneal Hazing 
 Delayed Wound Healing, 
 Ptosis (Steroid Myopathy). 
 Increased Intraocular Pressure (IOP) (68). 
 Growth Suppression (1,69). 
When SAC is refractory to all other treatment, topical corticosteroids 
can be considered for short-term treatment with vigilant monitoring (46,63). 
Medications such butyrate, have been used. Side effects like increased IOP and 
cataract formation limit their use(46,64) 
Loteprednol Etabonate0.2 %(LE) 
It is a ‘soft steroid,’ developed in view of reducing risks associated with 
raised IOP and cataract formation (64). It is an ester corticosteroid with a 17 b-
chloromethyl ester at the carbon-20 position instead of a ketone, a substitution 
that allows the drug to undergo predictable hydrolysis (70,71). In two 
randomized, double-masked placebo-controlled studies it is found that LE has 
similar safety profile with placebo(70,71).From a retrospective review of 159 
patients examined safety in patients using LE daily for more than 12 months 
and found no adverse effects related to its  long-term use(72).  
Ocular Therapeutic has developed technology for encapsulating 
ophthalmic drug preparations within a hydro gel to deliver sustained 
therapeutic levels of various drugs via punctual plugs (73). One example is 
OTX-DP, it is a dexamethasone depot preparation which is tested and is 
showing promising effect (74–76)on chronic allergic conjunctivitis treatment 
using CAC models. Other routes of drug administration are being explored 
even though topical corticosteroids are the most frequently used route for 
severe ocular allergy. The use of supratarsal injection of corticosteroids in 
severe VKCcases has shown improvement (74–76). A retrospective, 
noncomparative study of 35 childhood patients with refractory allergic 
keratoconjunctivitis suggested that supratarsal injection of triamcinolone 
acetonide was effective and safe, with only one patient experiencing elevated 
IOP (77). Prospective studies are needed in this respect. Intranasal 
corticosteroids (INSs), widely used in the treatment of allergic rhinitis, have 
also been examined with respect to treating ocular symptoms(78). The exact 
mechanism of reducing ocular symptoms is not known. Three possible 
mechanisms are one by inhibiting mast cells proliferation and recruitment 
(1,46,65–67).Second by decreasing the eosinophil production and third by 
inducing their apoptosis and phagocytic destruction (1,46,65–67). Numerous 
other effects like reducing the availability of histamine, both by increasing 
cellular stores and decreasing the expression of histamine receptors(67) in 
severe VKC (78).  
The INSs directly enter the eye via the nasolacrimal duct, decreased 
inflammation of the nasolacrimal duct improving drainage of allergens, or 
decreased nasal inflammation normalizes the excess reflex neural activity that 
occurs during allergic reactions (79). From many studies it is seen that  INS 
reduce the level of substance P in tear fluid ,suggesting  that substance P may 
have a significant role in naso-ocular interactions in allergic rhino 
conjunctivitis (80). The drugs like  mometasone furoate, fluticasone furoate, 
fluticasone propionate and budesonide (81–83) are promising ones for the 
treatment of AC. The meta-analysis of 10 randomized, placebo-controlled trials 
show that mometasone  furoate nasal spray are  effective at relieving ocular 
allergy symptoms in  allergic rhinitis patients(84).The  published data for INSs 
use in patients with rhinitis do not show an increased incidence of ocular 
hypertension, glaucoma or cataracts (83). In a study the effects of topical 
olopatadine and mometasone nasal spray in allergic subjects were assessed 
using the CAC and nasal allergen challenge (NAC) models of allergy. It is seen 
that the olopatadine provide effective management of both ocular allergy and 
nasal symptom(54). 
  
Topical NSAIDs 
Pharmacological properties of topical NSAIDS 
DRUG GROUP AGENTS 
MECHANISM  OF ACTION 
SIDE EFFECTS COMMENTS 
Topical non-steroidalanti-inflammatory 
agents 
KetorolacFlurbiprofenIndomethacinDiclofenac Inhibition ofCOX-1 and COX-2 resulting in PG inhibition 
Burning sensation, itching, corneal melt 
Used for postoperativeinflammation; notmuch effective in PAC and SAC 
 
Topical NSAIDs inhibit cyclooxygenase enzymes (COX-1 and COX-2) 
resulting in inhibition of inflammatory mediators such as prostaglandins and 
leukotrienes(85). They reduce pain, irritation and redness, and are used in 
treatment for post-operative inflammation. Many drugs have been tested for the 
treatment of ocular allergy, including ketorolac, flurbiprofen indomethacin and 
diclofenac. But they are generally ineffective or inferior to topical 
antihistamine therapy (1,86,87). Topical NSAIDs have side effects like burning 
and stinging, so these drugs have less patient compliance. Although for 
inflammation they are to be preferred corticosteroids whenever possible but 
topical NSAIDs are associated with the dangerous adverse effect of corneal 
melting, usually when there is a previous history ocular surface disease 
(1,88,89) 
  
Immunomodulatory therapy 
Pharmacological properties of immunomodulators. 
DRUG GROUP AGENTS MECHANISM  OF ACTION SIDE EFFECTS COMMENTS 
Topical immuno-modulatorytherapy 
Cyclosporine A Inhibition of T-cellactivation Irritation, burningsensation 
Approved for use in dry eye;  
 
Immunomodulatory drugs alter normal immune pathways and give a 
steroid-sparing alternative for allergic conjunctivitis. Different drugs in this 
group are cyclosporine A, tacrolimus, mycophenolate mofetil, leflunomide, 
rapamycin (sirolimus), copaxone, laquinimod and infliximab (90). Many of 
them have shown limited success because of their low water solubility and 
lipophilic properties leading to poor corneal penetration (50). Both 
cyclosporine and tacrolimus have shown promise results in treating severe and 
chronic inflammatory forms of ocular allergy. Cyclosporine A works by 
inhibiting T-cell activation and infiltration of eosinophil into the conjunctiva 
and they get involved with both late-phase and delayed-type allergic reactions 
(1,50,91).  
 The side effect like intense stinging with Cyclosporine A limit patient 
tolerance (92). Tacrolimus inhibits T-cell activation with a potent 
immunosuppressive effect, which is about 100 times stronger than that of 
cyclosporine (93). One common adverse effect is mild irritation of eye 
(94).Ointment formulations of tacrolimus shown to be effective as a steroid
sparing agent in both 0.1 and 0.03%concentrations 
DUAL-ACTING AGENTS
 
 
 
 
 
 
 
 
 
   
 
             Fig.2.6 : Action of dual 
(91,95). 
 
Fig.2.5 :Mechanism of itching 
acting agents 
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Pharmacological properties of dual acting agents. 
DRUG GROUP 
AGENTS 
MECHANISM  OF ACTION 
SIDE EFFECTS 
COMMENTS 
Topical dual-actingagents 
KetotifenAzelastineEpinastineBepostatineOlopatadineAlcaftadine Blockage ofH1 receptors andinhibits mast celldegranulation andhistamine release 
Headache, hyperemia,burning sensation, bittertaste, dry eye 
Most are used by twice daily dosing;Olopatadine and alcaftadine approved for once-daily dosingAlcaftadine shown to besuperior for ocular itching by many parameters 
 
Olopatadine and ketotifen are two drugs which are commonly used for 
different types of ocular allergy. Olopatadine0.1% is the first topical anti-
allergic drug, which was approved for twice-daily dosing (50). Ketotifen is 
used in many OTC anti-allergy drops. Azelastine has an extra mechanism of 
action of platelet-activating factor inhibition and intercellular adhesion 
molecule 1 expression, which are the main reasons for its efficacy in PAC (96). 
Epinastine blocks both H1 and H2 receptors competitively, which reduce eyelid 
edema (97). Epinastine have any CNS side effects as it does not cross the 
blood--brain barrier, compared to ketotifen, it has no effect on working 
memory in children (98). 
 Another difference from  topical antihistamines 
example, it is found from patients response that olopatadine and epinastine are 
more comfortable than azelastine, and  epinastine is more comfortable than 
ketotifen (49).In a study of 66 patients treated with bepotastine versus pla
it is shown that bepotastine produce  statistically significant decrease in non 
ocular-associated symptoms, including nasal congestion, rhinorrhea,ear palate 
pruritus and nasal pruritus 
for up to 8 h, allowing twice
approved for once-
pharmacological action with activity against H
reducing conjunctival eosinophil infiltration a
response (101). Olopatadine 0.2% and alcaftadine are the only anti
drugs available for once
 
 
 
 
 
 
 
Fig.2.7 Allergic Conjunctivitis Responses Phases 
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AIM 
To compare the efficacy and tolerability of olopatadine hydrochloride 
0.2% ophthalmic solution once daily with sodium cromoglycate 2%  
ophthalmic solution four times daily  in patients with allergic conjunctivitis 
Primary Objective 
To study efficacy of olopatadine hydrochloride 0.2% ophthalmic 
solution once daily with  sodium cromoglycate 2% ophthalmic solution four 
times  daily  in allergic conjunctivitis 
Secondary Objective 
To study tolerability of olopatadine hydrochloride 0.2%ophthalmic 
solution once daily with sodium cromoglycate 2% ophthalmic solution four 
times daily in allergic conjunctivitis . 
  
 
 
 
 
Methodology 
 
 
 
 
 
 
METHODOLOGY 
Study design: 
Randomized prospective, open labeled comparative study. 
Study population: 
Patients attending ophthalmology outpatient department of Chengalpattu 
medical college satisfying the eligibility criteria will be included in the study. 
Study centre: 
Chengalpattu Medical College Hospital 
Department of Pharmacology, in collaboration with Department of 
Ophthalmology Chengalpattu Medical College 
Period of study: 
March 2015 – February 2016 
Duration of study 
6 weeks 
4 weeks study and 2 weeks follow up per patients 
Sample size: 
120 patients 
Group A-olopatadine-60 patients 
Group B-Sodium Chromoglycate-60 patients 
Eligibility Criteria: 
Inclusion criteria: 
 All patients age > 4 years with clinically diagnosed allergic 
conjunctivitis. 
 Willing to  give written informed consent  
 Willing to do follow up visits.     
Exclusion criteria: 
 Patients age < 4 yrs. 
 Patient having active ocular infections, serious ocular pathological conditions 
 Patients havingocular surface disorders like pterygium, dry eyes 
blepharitis, history of ocular surgery within 3 months. 
 Patients who have known hypersensitivity to the study drugs including  
benzalkonium  chloride which is used as preservative in ophthalmic 
solution                   
 If the patient has used the study medications 1 week before the start of 
the study  
 Patients who are unwilling to discontinue contact lens during study 
period  
 Pregnant and lactating women. 
 Patient taking oral immuno-suppressive agents like steroids, topical 
medications, artificial tear drops, steroid eye drops. 
Study Procedure 
The study was conducted after obtaining the approval from Institutional 
Ethics Committee. Written informed consent was obrained from all study 
participant of age more than 18 years in a prescribed format in regional 
language after explainng about study purpose and study procedures.For the 
patients less than the age of 18 years ,their parents were explained about the 
study purpose and procedures and  a written informed consent was obtained 
from them. If the participant was illiterate, left thumb impression was sought. 
This was done in the presence of an impartial witness.  
Screening 
After getting informed consent, the demographic details of 145 patients 
were obtained and recorded. After taking complete medical history, clinical 
examination, slit lamp examination of eyes were done by an ophthalmologist. 
After screening145 patients, 120 patients who satisfy the inclusion and 
exclusion criteria were enrolled in the study during 1st visit. 
Randomization 
The enrolled patients were randomized by simple 
randomization(odd/even number) method  into group A or group B. 
 
Treatment Plan 
Group A-olopatadine hydrochloride 0.2% ophthalmic solution 1 drop on 
affected eye OD for 4 weeks 
Group B-sodium cromoglycate 2% ophthalmic solution1drop on affected eye 
QID for 4 weeks 
Follow Up Visits. 
After baseline (visit 1) history taking ,clinical examination, slit lamp 
examination of eyes of the patients in each group, group A and group B were 
given medications for 2 week. To assure compliance, the patients were asked to 
mark the time when they are instilling medication and record on his or her own 
impression on relief of symptoms during each day in a dairy ( provided during 
visit 1).The patients were also asked to return back the empty bottles of  
medications and diary during follow up visits. Follow up visits were made at 
2ndweek, 3rdweek and 4th week Adverse effects were noted during each visit 
and in case of any serious adverse effect patient were asked to report 
immediately to the hospital or investigator. After 4thweek medications were 
stopped and they were asked to come on 6th week for post treatment follow up.  
Visit 1 – Screening and enrolment 
 Informed consent obtained 
 Demographic details obtained 
 Randomization done 
 Medical history obtained 
 Vital signs recorded 
 General & systemic examination done 
 Examination of eyes done by ophthalmologist 
 Slit lamp examination done by ophthalmologist  
 Study medications given for  2 weeks 
 Parents  asked to return empty drug bottles and dairy during 
subsequent visits  
Visit 2 (2nd week) 
 Empty drug bottles and dairy received and compliance checked . 
 Vital signs recorded 
 General & systemic examination done 
 Examination of eyes done by ophthalmologist. 
 Slit lamp examination done by ophthalmologist. 
 Adverse events if any noted.  
 Study medications given for 1 week. 
 Subjects  asked to return empty drug bottles and dairy during 
subsequent visits. 
Visit 3(3rd week) 
 Empty drug bottles and dairy received and compliance checked 
 Vital signs recorded 
 General & systemic examination done 
 Examination of eyes done by ophthalmologist. 
 Slit lamp examination done by ophthalmologist. 
 Adverse events if any noted.  
 Study medications given for 1 week. 
 Subjects  asked to return empty drug bottles and dairy during 
subsequent visits.  
Visit 4(4th week) 
 Empty drug bottles and dairy received and compliance checked. 
 Vital signs recorded 
 General & systemic examination done 
 Examination of eyes done was by ophthalmologist.  
 Slit lamp examination done by ophthalmologist. 
 Adverse events if any monitored  
 Study medications were stopped 
 Subjects asked to return after 2 weeks. 
Visit 5 ( 6th week) Post Treatment Follow Up Visit  
 General & systemic examination done 
 Examination of eyes done by ophthalmologist. 
 Slit lamp examination done by ophthalmologist. 
 Adverse events if any noted. 
  
Assessment of Patients 
The assessment of patients is done by history taking ,clinical 
examination and slit examination by ophthalmologist. The ocular signs such as 
conjunctival congestion, chemosis, lid edema were assessed .the  signs are  
graded depending upon the severity (grade0-absent, grade1-mild, grade 2-
moderate, grade 3 severe).The ocular symptoms like itching, discomfort, 
stinging, photophobia and watering foreign body sensation were assessed by 
interviewing the patients and graded according to severity as grade 0-absent, 
grade1-mild, grade 2-moderate, grade 3 severe were assessed by interviewing 
the patients(3). 
Assessment of Efficacy, Safety and Tolerability. 
The change in mean scores from baseline for signs and symptoms  
during 2nd week  and 4th week were compared between two groups. Treatment 
related adverse events, compliance of patients are were compared between the 
two groups.  
  
STATISTICAL ANALYSIS 
The obtained data is analyzed statistically using SPSS 20 software . 
Descriptive data were analyzed by Chi square test.  
 The reduction of signs and symptoms scores during each visit from 
baseline scores during (visit1) within the groups were analyzed using wilcoxon 
signed rank test. Comparison between the groups A and group B in reduction 
of symptoms and signs scores were analyzed using Mann Whitney U test. 
P value <0.05 considered to be statistically significant. The collected 
data is computed into various tables and figures 
  
 
 
 
 
Results 
 
 
 
 
 
 
RESULTS 
This study was conducted to compare the efficacy and tolerability of 
olopatadine to sodium cromoglycate in allergic conjunctivitis patients. 
For the purpose of study 145pateints were screened, of which 25 were 
excluded from the study. Among 25 patients excluded, 10 patients not willing 
to give consent,11 patients not willing to stop other medications,3 were 
lactating mothers, one patient was not willing to stop using contact lens. 
 120 patients were included in the study, Of 120 patients 60 each was 
randomly allotted to group A and group B. Out of 120 patients,117 patients 
completed study. There was 1 drop out in group A and 2 drop outs in group B. 
These three drop outs were lost during follow up. 
  
 
STUDY FLOW CHART 
 
Fig : 5.1 Flow chart 
 
  
Table5.1 : Number Of Patients Completed And Number Of Dropouts
Groups Total no:of patients
Group A 60
Group B 60
Total 120
Table 1 shows total number of patients who completed the study and 
total number of drop outs from the study in both group A and group B.
Age Group A
<15 
>15 
Total 
Table 5.2 shows no statistically significant difference between group A 
and group B regarding age less  than 15 years and more than 15 years.
Figure 5.2shows age distribution 15years >age and age >15 years 
among group A and group B.
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Number ofpatients completed the study No: of drop 
 59 
 58 
 117 
Table 5.2: Age Distribution 
 Group B Chi SquareTest
36 35 X2 = 0.006
P=0.923 23 59 58 
Fig.5.2Age distribution 
 
35
23 23
AGE DISTRIBUTION
 
outs 
1 
2 
3 
 
 
 
 
 
 
<15
>15
Table 
Groups No. of patients
GROUP A 59
GROUP B 58
 
 
Table5.3: shows the mean age for group A is 16.03 years and 16.43 
years in group B. Pvalue is >0.05, means that there is no significant difference 
in mean ages between the groups.
 
Fig.5.3shows the mean age 
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5.3: Mean Age Distribution 
 Mean age (in years ) Sd Statistical Analysis
 16.03 11.791 P=0.858
 16.43 12.153 
 
Fig.5.3 Mean Age Distribution 
distribution in group A and group B
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Table5.4: Sex Distribution 
Sex distribution 
Groups 
Group A Group B PearsonChisquare test P Value n % n % 
Male 37 63 37 64 
X2=0.015 P=0.9 Female 22 37 21 36 
Total no. Of patients 59  58  
 
Table 5.4 shows sex distribution in groupA and group B. About 63% 
and 64% are males in group A and group B respectively. The females accounts 
for 37% and 36% in group A and group B respectively. Statistically there is no 
difference in sex distribution between the group. 
 
Fig.5.4: Sex Distribution 
Fig.5.4: a graphical representation showing sex distribution among 
group A and group B. 
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Table 5.5:Itching Scores 
Group A Group B MannWhitney U test 
Itching Mean Score+SD Mean Score+SD PValue 
Baseline 2.6+0.494 2.45+ 0.534 0.127 
visit 2(2nd week) 1.02+0.676 1.15+ 0.708 0.232 
visit 3(3rd week) 0.2 + 0.403 0.57+ 0.5325 0.01** 
visit4( 4th week) 0.1 + 0.237 0.25+ 0.473 0.04* 
Wilcoxon Signed Rank pvalue. 0.01** 0.01** 
*significant at P≤0.05, ** highly significant at P≤0.01,*** very high significant 
at P≤0.001 
 
 
Fig.5.5 : Itching Scores 
Visit 1-Baseline, visit 2- 2nd week, visit 3-3rd week, visit 4-4th week. 
Fig.5.5 shows graphical representation of itching scores during each visit. 
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 Table 5.5 shows mean itching scores with standard deviation at 
baseline(visit 1), 2ndweek(visit 2), visit 3(week 3) and visit 4(4th week).There 
is reduction in itching score from baseline(visit 1) at visit 2,visit3, visit 4. 
Wilcoxon  singed rank test  is used to compare the reduction in itching score 
between baseline visit and  2ndweek(1-2), 3rd week(1-3), 4th week(1-4), there is 
statistically significant [p vale<0.01] difference in both group A and group B. 
Mann Whitney  U test is used to compare group A and  group B at visit 
1,visit2,visit 3,visit 4.There  is no difference in itching score between the 
groups at baseline visit[p value >0.05].There is statistically significant 
difference in itching score at visit 3 and visit 4.[ p value<0.05] 
Table5.6: Mean Reduction In Itching Score At 2nd week and 4th week 
  
  
Mean change at 2nd week Mean change at 4th week 
group A group B P value group A group B P value 
Itching Score 1.58 1.4 0.248 2.5 2.2 0.006** 
 
Table 5.6 shows comparison between mean change in itching score at 
2nd week and 4th week.  
There is no difference in mean change in itching score at 2nd week in 
both group A and Group B statistically [p value>0.05]. There is statistically 
significant difference between the group A and group B during 4th week [P 
value<0.05] in reduction of itching. 
 
 Fig. 5.6 Change In Itching Score at 2ndweek and 4
 Fig.5.6 : a graphical representation of mean change 
2nd week and 4th week. Mean change is more in group A during 2
week. 
Fig
Fig.5.7shows graphical representation of
itching.      
  The patient whose score is 0 is 
25% patients score become zero by 2
and 89% get cured by 4th week.   In group B it was about 10%, 46% and 76% 
during 2nd week, 3rd week and 4
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Table5.7:Redness Score 
  Group A Group B Mann whitney U test 
Redness MEAN   SCORE+ SD MEAN SCORE+ SD pValue 
Baseline 2.51  +  0.504 2.4  + 0.560 0.367 
visit 2 1.23 +  0.722 1.25 + 0.531 0.857 
visit 3 0.42  + 0.532 0.65 +0.503 0.037* 
visit4 0.15 + 0.363 0.43 +   0.479 0.001*** 
Wilcoxon Signed Rank test pvalue P< 0.001*** P< 0.001***  
*significant at P≤0.05,** highly significant at P≤0.01,*** very high significant 
at P≤0.001 
 
 
 
Fig.5.8Redness Score 
Visit 1-Baseline, Visit 2- 2nd week, Visit 3-3rd week,Visit4-4th week. 
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Table 5.7 shows mean redness score at visit-1, visit-2,visit 3,visit 4. 
There is no statistically significant difference between the groups at visit 
1(baseline) [p value>0.05]. Comparison within the 
Group is done by Wilcoxon Signed Rank text and between the groups 
done by mann whitney  U test. There is significant difference in reduction of 
redness  scores between the groups during 3rd visit and 4th visit.[ P value< 
0.05].Both the treatment is effective in reducing  redness score from baseline 
score [P value<0.001,very highly significant.]. 
Fig.5.8:a graphical representation showing  mean redness score at visit 
1,visit 2,visit 3,visit 4. There is decrease in mean redness score from visit 1 to 
visit 4 .In group A, the mean redness score reduced from 2.51 to 0.15.In group 
B, the mean redness score reduced from 2.4 to 0.43. In both group the 
reduction in redness score from visit 1 to visit 4 is statistically significant (by 
wilcoxon test).When we compare the reduction in redness score between 
groups. There is a statistically significant difference in the reduction of redness 
score in group A compared to group B during visit 3 and visit 4. 
Table 5.8 : Mean reduction in redness score in 2nd week and 4th week 
  Mean change at 2nd week Mean change at 4th week 
  group A group B P value group A group B P value 
Redness Score 1.26 1.15 0.350 2.36 1.96 0.002 
*significant at P≤0.05,** highly significant at P≤0.01,*** very high significant 
at P≤0.001 
Table 5.8 shows comparison, mean change in redness score during 2
week and 4th week between the groups. There is a significant difference 
between the groups during 4
[P value<0.01].Reduction is more in group A compared to group B 
which is statistically significant during 4
Fig.5.9:Change 
Fig.5.9 shows graphical representation showing mean change in redness 
score from baseline during 2
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Fig:5.10shows graphical representation of
redness.      
  The patient whose score is 0 is considered as responders. In group A 
32% patients redness score become zero by 2
week and 84% cured at 4th week. In group B it was about 5%, 47% and 66% 
during 2nd week, 3rd week and 4
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Table5.9 :Chemosis Score 
Chemosis Group A GroupB MannWhitneyUtest 
visits Mean Score+ SD MeanScore+SD P value 
Basline 0.85+0.685 0.70+0.618 0.238 
visit 2 0.24+ 0,426 0.30+ 0.462 0.411 
visit 3 0.1+ 0.302 0.12+ 0.342 0.571 
visit 4 0.00+ 0.000 0.03+ 0.181 0.156 
Wilcoxon signed rank test P< 0.001*** P<0.001***   
*significant at P≤0.05,** highly significant at P≤0.01,*** very high significant 
at P≤0.001 
 
 
Fig.5.11Chemosis Scores 
Visit 1-Baseline ,Visit 2- 2nd week, Visit 3-3rd week,Visit4-4th week 
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Fig:5.11  shows a graphical representation of mean scores of chemosis 
at each  visit. Table 5.9
at each visit. The mean scores reduce from 0.85 at baseline visit to 0.00 during 
4th visit in group A and in group B the mean score reduce from0.7 to0.03 at 
visit 4. 
The reduction of chemosis in both g
significantP value<0.001 by Wilcoxon signed rank test.
When the group A is compared with group B there is no significant 
difference statistically in reduction in chemosis score at visit 2(2
3( 3rdth week) and visit 4( 4
Fig.5.
Fig 5.12 shows a graphical representation of % responders in group A 
and group B for chemosis score.
The patients whose scores are 0 at visit 2, visit 3,visit 4 are 
as responders. During 2
score0.100% patients in group A attained score 0 at 4
53%, 77% and 94% become responders at week 2,week 3 and week 4 
respectively. 
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Table5.10: Lid Edema Scores 
Lid  Edema Group A Group  B 
Mann Whitney U test 
Mean Score+ SD Mean Score+ SD P VALUE 
Baseline (visit 1) 0.69 + 0.65 0.61 + 0.62 0.603 
visit 2 0.25 +0.439 0.28+0.459 0.681 
visit 3 0.1 + 0.305 0.12 + 0.329 0.77 
visit 4 0.02 + 0.13 0.08 + 0.283 0.095 
Wilcoxon Test P < 0.001 P<0.001   
*significant at P≤0.05,** highly significant at P≤0.01,*** very high significant 
at P≤0.001 
Visit 1-Baseline ,Visit 2- 2nd week, Visit 3-3rd week,Visit4 4th week 
 
Fig.5.13Lid  Edema Scores 
Fig.5.13 shows a graphical representation of mean scores of lid edema 
during each visit.  
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Table 5.10 shows mean lid edema scores with standard deviation .There 
is reduction in mean lid edema scores from visit 1 at visit 2,visit3, visit 4.Both 
in group A and Grou
swelling score and is statistically significant.(Wilcoxon signed rank test 
P<0.001) in group A and group B respectively)
When we compare the mean lid edema scores between group A and 
group B There is no statistically significant difference between the treatment in 
groups by Mann Whitney U Test.(the p value>0.05 during all visits.)
Fig5.14
Fig.5.14 a graphical representation of % responders in group A and 
group B for lid edema scores
score is 0 are taken as responders.In group A there is 57%, 83%,and 97% 
responders during 2nd 
there is 45%, 77% and 84% responders during 2
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Table 5.11 Tearing Scores 
  Group A Group B Mann Whitney U Test 
Tearing Mean Score+SD  Mean Score+SD  P value 
visit 1(Baseline) 1.33 +0.617 1.34+0.515 0.769 
visit 2 0.29+0.457 0.31+0.467 0.991 
visit 3 0.12+0.305 0.05+0.223 0.188 
visit 4 0.02+130 0.03+0.184 0.56 
Wilcoxon signed rank test P < 0.001* P<0.001*  
*significant at P≤0.05,** highly significant at P≤0.01,*** very high significant 
at P≤0.001 
Visit 1-Baseline ,Visit 2- 2nd week, Visit 3-3rd week, Visit4-4th week 
 
Fig.5.15Tearing Scores 
Table 5.11 shows mean tearing  scores with standard deviation during 
each visit is given in the table .There is a reduction in mean tearing scores from 
visit 1 at visit 2, visit 3,visit 4. 
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Both in group A and Group B the treatments are effective in reducing 
symptom tearing which is statistically highly significant. (Wilcoxon signed 
rank test p< 0.001 in both group A and group B ).When we compare mean 
tearing scores between group A and group B There is no statistical significant 
difference in tearing score between the
p value>0.05 during all visits). 
Fig.5.15 shows a graphical representation of mean tearing scores during 
each visit.           
Fig.5.
Fig.5.16 a graphical representation of % responders in group A and 
group B for symptom tearing. 
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16 %Responders in tearing scores 
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Table 5.12 Discomfort Scores 
Discomfort Group A Group B 
Mann  Whitney U test 
Mean Score  + SD Mean Score + SD Pvalue 
Visit 1(Baseline) 1.67 + 0.876 1.60+0.527 0.886 
visit 2 0.62+ 0.738 0.65+0.633 0.574 
visit 3 0.283+0.454 0.30+0.497 0.954 
visit 4 0.07+0.252 0.08+0.278 0.780 
Wilcoxon signed rank test P<0.001*** P<0.001***  
*significant at P≤0.05,** highly significant at P≤0.01,*** very high significant 
at P≤0.001 
Visit 1-Baseline , Visit 2- 2nd week, Visit 3-3rd week, Visit4 -4th week 
 
Fig.5.17 Discomfort Scores 
Table5.12 shows mean discomfort scores with standard deviation during 
each visits. 
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There is a reduction in mean discomfort scores from visit 1 at visit 2, 
visit 3,visit 4. 
In group A and Group B the treatments are effective in reducing 
discomfort scores is statisti
P<0.001) in both group A and group B 
When we compare the reduction in discomfort scores between group A 
and group B during each visit, there is no statistically significant difference in 
reduction of discomfort
Test, p value > 0.05 during visit 2, visit 3 and visit 4].
Fig.5.17 shows a graphical representation of mean discomfort scores 
during each visit. 
Fig.5.18 %Responders  in discomfort scores
Fig.5.18 shows a graphical representation of  % responders in group A 
and group B  for discomfort symptom .
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whose score is 0 are taken as responders. In group A there is 55%, 75%and89% 
responders for symptom discomfort during 2nd week, 3rd week and 4th week 
respectively. In group B there is 49%, 66% and 86% responders for symptom 
discomfort during 2nd week, 3rd week and 4th week respectively 
Table 5.13: Photophobia Scores 
Photophobia Mean Score+SD Mean Score+  SD. Mann Whitney U testP value 
visit 1( Baseline) 0.46 +0.502 0.32+0.467 0.135 
visit 2 0.08+0.183 0.06 + 0.256 0.834 
 visit 3 0.00+ 0.000 0.02  +0.131 0.317 
visit 4 0.00+0.000 0.00+ 0.000 1.000 
Wilcoxon  Rank Sum Test P< 0.0001* P < 0.0001* 
*significant at P≤0.05,** highly significant at P≤0.01,*** very high significant 
at P≤0.001 
Visit 1-Baseline, Visit 2- 2nd week, Visit 3-3rd week, Visit4 -4th week. 
 
Fig.5.19 Photophobia Scores 
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Table 5.13 shows mean photophobia scores with standard deviation 
during each visitFig 19 shows a graphical representation of mean photophobia 
scores during each visit.There is a reduction in mean photophobia scores from 
visit 1at visit 2,visit 3,visit 4.Both in group A and group B, the reduction of 
photophobia score is statistically signifi
are effective in reducing photophobia.
When we compare the reduction in photophobia scores between group A 
and group B during each visit, there is no statistically significant difference 
between the groups  in reductio
visit 2, visit 3, visit 4.] 
Fig.5.20
Fig.5.20 shows a graphical representation of % responders in group A 
and group B  for  symptom photophobia .
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93%responders during 2
symptom photophobia. 
In group B there is 82%  responders during 2
during 3rd week and 100% responders during 4
photophobia. 
0
20
40
60
80
100
Visit
93
Res
pon
der
s %
cant.( P< 0.001) . So both treatments 
 
n of discomfort score [ p value > 0.05 during  
%Responders  in Photophobia Scores 
During  visit 2,visit 
nd week, and 100% responders during  3
nd week, 94% responders 
th week for symptom 
-2 Visit -3 Visit-4
100 10082 94 100
% Responders  for  Photophobia
 
3,visit 4 the 
rd week for 
GROUP A
GROUP B
Table 5.14: Foreign Body Sensation Scores 
Foreign Body Group A Group B 
Mann Whitney U test 
Mean Score+ SD Mean Score +SD P value 
Visit 1(Baseline) 2.28 + 0.457 2.12 + 0.564 0.079 
Visit  2 0.52 + 0.598 0.40  + 0.459 0.262 
Visit 3 0.07  +0.254 0.02  +0.131 0.730 
Visit 4 0.00+0.000 0.03+0.033 0.156 
Wilcoxon signed rank test P<0.001*** P<0.001***  
*significant at P≤0.05, ** highly significant at P≤0.01,*** very high significant 
at P≤0.001 
Visit 1-Baseline, Visit 2- 2nd week, Visit 3-3rd week, Visit4 -4th week                     
 
Fig.5.21Foreign Body Sensation Scores 
Table 5.14 shows  mean foreign body sensation scores with standard 
deviation during each visit 
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Fig.5.21 shows a graphical re
sensation scores during each visit. There is a reduction in mean foreign body 
sensation scores from visit 1at visit 2, visit 3, visit 4.Both in group A and group 
B, the reduction of foreign body sensation score is statisti
0.001). So both treatments are effective in reducing foreign body sensation.
When we compare the reduction in foreign body sensation between 
group A and group B during each visit, there is no statistically significant 
difference between the groups in reduction of foreign body sensation [p value > 
0.05 during visit 2, visit 3, visit 4.]
Fig.5.22%Responders  in Foreign Body Sensation Scores
Fig.5.22  shows a graphical representation of % responders in group A 
and group B  for  symptom
3,visit 4 the patient whose score is 0 are taken as responders.
In group A there is 71% responders during 2
during  3rd week and 100% responders for symptom
In group B there is 66 % responders during 2
during 3rd week and 98% responders during 4
sensation. 
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Table 5.15: Stinging Scores 
Stinging Mean Score+ SD Mean Score+ SD Mann Whitney U test (Pvalue) 
Visit 1(Baseline) 2.27 + 0.485 2.1 +0.667 0.358 
Visit 2 0.15 +0.363 0.217 +0.627 0.451 
Visit 3 0.07 +0.254 0.133+0.438 0.225 
Visit 4 0.02 +0.13 0.05+0.329 0.172 
Wilcoxon signed rank test P<0.001* P<0.001*  
*significant at P≤0.05,** highly significant at P≤0.01,*** very high significant 
at P≤0.001 
Visit 1-Baseline, Visit 2- 2nd week, Visit 3-3rd week, Visit4 -4th week. 
 
Fig.5.23: Stinging Scores 
Table 5.15 shows mean stinging scores with standard deviation during 
each visitFig.5.23 shows a graphical representation of mean stinging scores 
during each visit. There is a reduction in mean stinging scores from visit 1at 
visit 2, visit 3,visit 4.Both in group A and group B, the reduction of stinging 
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Fig.5.24shows a graphical representation of % responders in group A 
and group B  for  symptom for stinging sensation .
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Table 5.16:Mean Change in Signs and Symptoms at 2nd week  
and 4th week. 
  
  
Mean change from 
baseline in 2 nd week 
Mean change from 
baseline in 4th week 
Mannwhitney 
U test 
Group 
A 
Group 
B P value Group A Group B P value 
Redness 1.26 1.15 0.350 2.36 1.96 0.002** 
Itching 1.58 1.40 0.248 2.55 2.22 0.006** 
Chemosis 0.62 0.4 0.06 0.85 0.67 0.152 
EyeLid 
Edema 0.43 0.33 0.318 0.67 0.53 0.262 
watering 1.01 1.033 0.668 1.28 1.3 0.889 
photophobia 0.37 0.23 0.113 0.45 0.32 0.135 
discomfort 1.05 0.95 0.291 1.6 1.51 0.790 
Foreignbody 
Sensation 1.75 1.72 0.683 2.28 2.08 0.087 
Stinging 2.05 1.87 0.058 2.18 2.02 0.138 
*significant at P≤0.05,** highly significant at P≤0.01,*** very high significant 
at P≤0.001 
Table 5.16 show change from baseline score during visit 2 ( 2nd week)  
and visit 4( 4th week) 
 
 
Table 5.17 : Adverse Events 
Groups    Adverse events Total Chi square test Present Absent 
59 X2 =1.905 Group A 5 54 
Group B 9 49 58 P=0.138 
 
 Table 5.17 show the adverse events in group A and Group B. In group 
A, 2 patients had sinusitis and 3 patients had fever. In group B, 5 patients had 
sinusitis and 4 patients had fever. In both groups there is no treatment related 
adverse events. There is no significant difference between the group A and 
group B statistically on adverse effect occurrence [P value>0.05]. 
Table 5.18:Safety Parameters Observed 
Parameters Observed Group A Group B 
IOP Changes Nil Nil 
Visual Acuity Changes Nil Nil 
Fundoscopy changes Nil Nil 
Stinging Nil Nil 
Blurring of Vision Nil Nil 
Headache Nil Nil 
 
Table 5.18 shows the safety parameters measured during  all visits. 
 
 
  
 
 
 
Discussion 
 
 
 
 
 
DISCUSSION 
To choose the best drug in allergic conjunctivitis with understanding of 
underlying mechanisms implicated  in triggering the allergy is very important. 
Olopatadine with a wide action spectrum has shown to be very effective in 
allergic conjunctivitis(103). In this study the patients with allergic 
conjunctivitis in ophthalmic OPD were randomized into group A and group B. 
In group A patients were given olopatadine0.2% once daily for 4 weeks and in 
group B sodium cromoglycate 2% four times daily. The efficacy and 
tolerability of the drug olopatadine were compared to that of drug sodium 
cromoglycate. The results of the study are discussed here. 
From 120 patients who were randomized to group A and group B 117 
patients completed the study. Three patients were lost in follow up.59 patients 
in group A and 58 patients in group B completed the study. In group A there 
were 36 patients in age group less than 15 years and 23 patients of age more 
than 15 years. In goup B there were 35 patients of age less than 15 years and 23 
patients of age more than 15years. There is no difference between groups in 
age distribution during baseline visit. 
The mean age for group A is 16.03 years and in group B I s16.43 years. 
There is no significant difference in mean ages between the groups. There is 
63% males in group A and 64% males in group B . The females accounts for 
37% and 36% in group A and group B respectively. Statistically there is no 
difference in sex distribution between the group. 
In this study the mean itching score in group A and group B during 
baseline visit are 2.6 and 2.45 respectively. The itching scores in both groups 
are comparable during baseline visit [ p value>0.05].  There is no significant 
difference in reduction of itching  between the groups (3)during 2nd  week 
.During 4th week(3) the reduction of  itching scores in group A  was more 
compared to group B which is statistically  significant. When mean reduction 
from baseline in itching score was compared  between group A and group B 
there is significant reduction  in group A during 4th week. [P value<0.05] .The 
percentage of responders are more in group A compared to group B during all 
visits. Both treatment are effective in treating itching [p value<0.01, p 
value<0.01]. 
The mean redness score during baseline is 2.5 in group A and 2.4 in 
group B. There is no significant difference between the groups in mean 
baseline score during visit1 [ P value > 0.05].The redness score reduced from 
2.5 to0.15 during  4th week  in group A[ pvalue<0.001]. In group B the redness 
score reduced from 2.4 to 0.433 during 4th week[ pvalue<0.001].Both treatment 
A and treatment B is effective in reducing redness When we compare the 
reduction in redness score, it is more in group A during 2nd week but the 
difference is not  significant[P value>0.05]. During 4th week the reduction in 
redness score in group A is significant compared to group B*[P value <0.01].  
When we compare the change from baseline redness score during 2nd week and  
4th  week  there is significant difference during 4th week [ P value >0.05] similar 
to other studies.(3)The percentage responders in redness are higher in group A 
during 2nd week,3rd week, and 4th week compared to group B similar to other 
studies.(3) 
The mean chemosis score in group A during first visit is 0.85 and in 
group B is 0.7. In group A 0.85 reduced to 0.00 during visit 4 and in group B 
0.7 reduced to 0.03 during visit 4There is no significant difference between the 
groups during visit-1[p value>0.05].Both in group A and Group B, treatments 
are effective in reducing chemosis score from baseline score[P value 
<0.001].The reduction in mean chemosis scores are more in group A compared 
to group B .This difference is not statistically significant. The percentage 
responders in chemosis score are higher in group A during 2nd week, 3rd week, 
and 4th week compared to group B. 
The mean lid edema scores during baseline is 0.68 in group A and 
0.61in group B. There is no difference in mean score during (baseline) visit1  
[P value > 0.05].The lid edema scores reduced from 0.68to0.02 and 0.61 to0.08 
during visit 4 in group A and  group B respectively. Both treatment A and 
treatment B is effective in reducing lid edema scores [P 
value<0.001,Pvalue<0.001]. There is no significant  difference in reduction of 
lid edema scores between group A and group B [P value>0.05]. The percentage 
responders in lid edema scores are higher in group A during 2nd week, 3rd week, 
and 4th week compared to group B 
The mean tearing scores during baseline is 1.33 in group A and 1.34in 
group B. There is no difference in mean score during (baseline) visit 1[ P value 
> 0.05].The tearing scores reduced from 1.33 to0.02 in group A  and from 1.34 
to0.03 in group B during visit 4. Both treatment A and treatment B are effective 
in reducing tearing scores [P value<0.001, P value<0.001].There is no 
significant difference in reduction of tearing scores between group A and group 
B [P value>0.05]. The percentage responders tearing scores are higher in group 
A during 2nd and 4th week compared to group B. 
The mean discomfort score in group A during visit1 is 1.68 and in group 
B is1.60.There is no statistical difference between the groups during visit- 1[ p 
value>0.05].Both in group A and Group B, treatments are effective in reducing 
discomfort score from baseline score [P value <0.001].In group A 1.68 is 
reduced to 007.during visit 4 and in group B 1.60 is reduced to 0.08 during visit 
4. The difference in reduction of discomfort scores between group A and group 
B are not statistically significant [ P value>0.05]. The percentage responders in 
discomfort scores are higher in group A during 2nd week, 3rd week, and 4th 
week compared to group B. 
The mean photophobia scores in group A during visit-1 is 0.46 and in 
group B is 0.32.There is no statistical difference between the groups during 
visit- 1[ p value>0.05].Both in group A and Group B, treatments are effective 
in reducing photophobia symptom. [P value <0.001]. The difference in 
reduction of photophobia score between group A and group B are not 
statistically significant. [ p value>0.05]. The percentage responders in 
photophobia  scores are higher in group A during 2nd week,3rd week, and 4th 
week compared to group B. 
The mean foreign body sensation scores in group A during visit-1 is 
2.28 and in group B is 2.12.There is no significant difference between the 
groups during visit- 1[ p value>0.05].Both in group A and Group B, treatments 
are effective in reducing foreign body sensation [Pvalue <0.001].In group A 
2.28 reduced to 0.00 during visit 4 and in group B 2.12 reduced to 0.03 during 
visit 4.The reduction in mean foreign body sensation scores are more in group 
A compared to group B .this difference in reduction is not significant. The 
percentage responders in foreign body sensation scores are higher in group A 
during 2nd week, 3rd week and 4th week compared to groupB. 
The mean stinging scores during baseline is 2.27 in group A and 2.12 in 
group B. There is no difference in mean score during (baseline) visit1 [  P value 
> 0.05].The stinging scores reduced from 2.27 to0.02 in group A  and from 2.1 
to 0.05 in group B during visit 4..The mean stinging scores reduced in both 
groups. Both treatment A and treatment B is effective in reducing stinging 
scores [P value<0.001, P value<0.001]. But there is no difference in reduction 
of stinging scores between the groups [Pvalue>0.05].The percentage 
responders stinging scores are higher in group A during 2nd , 3rd and  4th week 
compared to group B.  
The adverse events occurred in 14 participants out of 117 participants,5 
in group A and 9 in group B. There is no significant difference between the 
groups[ P value >0.05].The adverse events noted were fever and rhinitis. There 
is no treatment related adverse events in both groups during 2nd visit, 3rd visit, 
4th visit and 5th visit ( 6th week).There is no serious adverse events observed 
during the study. 
During follow up visit at 6th week safety parameters like IOP changes, 
visual acuity changes, fundoscopic changes were examined. Patients in both 
groups give no history of stinging, blurring of vision, headache during the visit. 
No changes in safety parameters are noted in both groups. 
The compliance of patients are more in group A  compared to group B 
on the basis of  empty bottles count , patient’s diary record and  interview with 
patient during visit2,visit 3 and visit 4. 
  
 
 
 
 
Summary 
 
 
 
 
 
 
SUMMARY 
This study is an open labeled randomized comparative study of 
olopatadine 0.2% once daily dose with 2% sodium cromoglycate four times 
daily. 
After following inclusion and exclusion criteria 120 patients were 
randomized into 2 groups group A  and group B .Group A received olopatadine 
0.2% once daily dose and group B received 2% sodium cromoglycate four 
times daily for four weeks. During the study 3 patients were lost to follow 
up.117 patients completed the study. 
This study show that both olopatadine 0.2% single dose  and 2%  
sodium cromoglycate four times daily are equally effective in providing relief 
from signs and symptoms of allergic conjunctivitis during 2nd week. Compared 
to 2% sodium cromoglycate, 0.2% olopatadine single dose produce better 
reduction of itching and redness of eye during 4th week. Number of responders 
were more in olopatadine group .There were no treatment related adverse 
effects in both groups. 
Both drugs were equally safe and tolerable. Patient compliance was 
more with 0.2% olopatadine single dose when compared to 2% sodium 
cromoglycate four times daily 
 
 
 
 
 
 
Conclusion 
 
 
 
 
 
 
CONCLUSION 
From this study we can conclude that 
Both olopatadine 0.2% 1 drop once daily and sodium cromoglycate 2% 
1 drop four times daily are effective in reducing symptoms and signs of allergic 
conjunctivitis during  2nd  and 4th week. 
Olopatadine 0.2% once daily is found to be more effective than sodium 
cromoglycate 2% four times daily in reducing redness and itching scores 
during 4th week. 
Treatment with Olopatadine 0.2% once daily has more patient 
compliance than sodium cromoglycate2% four times daily. 
Both olopatadine 0.2% once daily and sodium cromoglycate 2% four 
times daily  show good  patient tolerability and safety profile. 
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Annexures 
  
LIST OF ABBREVIATIONS  
AC  –  Allergic Conjunctivitis 
AKC  –  Atopic Keratoconjunctivitis 
CAC  –  Conjunctival Allergen Challenge 
CDC  – Contact Dermato Conjunctivitis 
Cox-1  – Cyclo-Oxygenase -1 
Cox-2  – Cyclo-Oxygenase-2 
DC   – Dendritic Cells 
GPC  –  Giant Papillary Conjunctivitis 
h  –  Hour 
H1 H2 H3H4 – Histamine Receptors(1,2,3,4). 
HETE  – Hydroxyeicosatetraenoic acid 
HHT   – Heptadecatrienoic. 
HPETE  – Hydroperoxyeicosatetraenoic acid 
ICAM-1 – Intercellular adhesion molecule-1 
IgE  – Immunoglobulin E 
INS  – Intra Nasal Steroids 
IOP  – Intraocular Pressure 
LE  – Lotrendol Etabonate 
LT  – Leukotriene 
MCP  – Monocyte chemoattractant protein 
MDA  – Malonyldialdehyde, 
MMP  – Matrix Metalloproteinase 
NAC  – Nasal Allergy Challenge 
NSAID – Non Steroidal Anti-inflammatory Drugs 
OPD  – Out Patient Department 
OTC  – Over The Counter 
PAC  – Perennial Allergic Conjunctivitis 
PAF  – Plateletactivating 
PG  – Prostaglandins  
SRS-A  – Slow-reacting substance of anaphylaxis 
SAC    – Seasonal Allergic Conjunctivitis 
TH-2  – T helper cels 2 
VKC  – Vernal kerato Conjunctivitis 
  
  
 
  
 
  
INFORMED CONSENT FORM 
(This is only a guideline –Relevant changes to be made as per the study requirements) 
Title of the study: “A RANDOMIZED PROSPECTIVE OPEN LABEL COMPARATIVE STUDY OF OLAPATADINE WITH SODIUM CROMOGLYCATE IN ALLERGIC CONJUNCTIVITIS”  
Name of the patient  :_________________________________________ 
Name of the Investigator : Dr  SANU SAIN 
Name of the Institution : Chengalpattu Medical College Hospital 
Documentation of the informed consent. 
I _________________________________have read the information in this form (or it has been read to me).I was free to ask any questions and they have been answered. I am over 18 years of age and, exercising my free power of choice, hereby give my consent to be included as a participant in ‘“A RANDOMIZED PROSPECTIVE  OPEN LABEL COMPARATIVE STUDY OF OLAPATADINE WITH SODIUM CROMOGLYCATE IN ALLERGIC CONJUNCTIVITIS” 
1. I have read and understand this consent form and the information provided to me. 2. I have had the consent document explained to me. 3. I have been explained about the nature of the study. 4. I have been explained about my rights and responsibilities by the investigator. 5. I have been informed the investigator of all the treatments I am taking or have taken in the past______________________including any native (alternative) treatment. 6. I have been advised about the risks associated with my participation in this study. 7. I agree to cooperate with the investigator and I will inform him/her immediately if I suffer unusual symptoms. 8. I have not participated in any research study within the past__________________. 9. I have not donated blood within the past_________________- Add if the study involves extensive blood sampling. 10. I am aware of the fact that I can opt out of the study at any time without having to give any reason and this will not affect my future treatment in this hospital. 11. I am also aware that the investigator may treatment my participated in the study at any time for any reason, without my consent. 12. I hereby give permission to the investigators to release the information obtained from me as result of participation in this study to the sponsors, regulatory authorities, Govt.Agencies, and IEC. I understand that they are publicly presented. 13. I have understood that my identity will be kept confidential if my data are publicly presented. 14. I have had my questions answered to my satisfaction. 15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the Investigator. By signing this consent form I attest that the information given in this document has been clearly explained to me and understood by me, I will be given a copy of this consent document. 
For adult participants: 
Name and signature/thumb impression of the participant (or legal representative if participant incompetent) 
Name______________________signature__________________Date____________ 
Name and signature of impartial witness (require for illiterate patients) 
Address and contact number of the impartial witness: 
Name______________________signature__________________Date____________ 
Name and signature of the investigator or his representative obtaining consent: 
Name______________________signature__________________Date____________ 
For children being enrolled in research: 
Whether child’s assent was asked: Yes/No 
(If the answer to be above question is Yes,write the following phrase: 
You agree with the manner in which assent was asked for from your child and given by your child. You agree to have your child take part in this study. 
(If answer to be above question No, give reason:_____________________________ 
Although your child did not or could not give his or her assent, you agree to your child’s participation in this study. 
Name and signature of/thump impression of the participant’s parent(s) (or legal representatives) 
Name______________________signature__________________Date____________ 
Name______________________signature__________________Date____________ 
Name and signature of impartial witness (require for parents of participant child illiterate): 
Address and contact number of the impartial witness: _________________________ 
_____________________________________________________________________ 
  
Name and signature of the investigator or his representative obtaining consent: 
Name______________________signature__________________Date____________ 
NOTE:- 
For observational studies in nature or those in which only patient’s tissue, body fluids are collected for any kind of analysis the following elements in the patient information leaflet will need be included – background of the study the purpose for which the sample will be used: confidentially of data are right to refuse to give specimens should be included. 
Points 6, 7,8,9,10,11 of consent document may be excluded in such cases. 
  
BWônf£ Jl×Rp L¥Rm 
 
BWônf£ RûXl×: 
 
ùNeLpThÓ AWÑ ùTôÕ UÚjÕYUû]«p Li 
£¡fûN SXl©¬®p JqYôûU ®¯ ùYiTPX AZt£ 
úSôndÏ YZeLlTÓm JXlTôh¥¥u ûa¥úWô 
Ïú[ôûWÓ, úNô¥Vm Ïú[ôûWÓ, úNô¥Vm ÏúWôúUô 
¡û[dúLÓ B¡V UÚkÕL°u TVuTôÓ Utßm TôÕLôl× 
Ï±jRô] JlÀhÓ BnÜ. 
 
ùTVo   :    úR§  : 
YVÕ   :    BWônf£ úNodûL Gi: 
Tô­]m : 
 
 G]dÏ A°dLlThP RLYp T¥Yj§p Es[ 
®`VeLû[l T¥jÕm úLhÓm ×¬kÕ ùLôiúPu. 
 CkR BWônf£«p ©\¬u ¨oTkRªu± Gu ùNôkR 
®ÚlTj§u úT¬p Sôu TeÏ ùTß¡ú\u. 
 Bn®p ùRôPokÕ TeÏùT\ ®ÚlTm 
CpûXùVu\ôp ®X¡d ùLôs[Xôm Guß A±kÕ 
ùLôiúPu. 
 Bn®u Ø¥®û] ùNôkR AûPVô[eLû[ 
ùY°«PôUp UÚjÕY BWônf£dLôL TVuTÓj§d 
ùLôs[ NmU§d¡ú\u. 
 
ÏZkûRLÞdLô] BWônf£ Jl×Rp L¥Rm 
 
BWônf£ RûXl×: 
 
ùNeLpThÓ AWÑ ùTôÕ UÚjÕYUû]«p Li £¡fûN 
SXl©¬®p JqYôûU ®¯ ùYiTPX AZt£ úSôndÏ 
YZeLlTÓm JXlTôh¥¥u ûa¥úWô Ïú[ôûWÓ, úNô¥Vm 
Ïú[ôûWÓ, úNô¥Vm ÏúWôúUô ¡û[dúLÓ B¡V 
UÚkÕL°u TVuTôÓ Utßm TôÕLôl× Ï±jRô] JlÀhÓ 
BnÜ. 
 
ùTVo   :    úR§  : 
YVÕ   :    BWônf£ úNodûL Gi: 
Tô­]m : 
  G]dÏ A°dLlThP RLYp T¥Yj§p Es[ 
®`VeLû[l T¥jÕm úLhÓm ×¬kÕ ùLôiúPu. 
 CkR BWônf£«p ©\¬u ¨oTkRªu± Gu ùNôkR 
®ÚlTj§u úT¬p Sôu TeÏ ùTß¡ú\u. 
 Bn®p ùRôPokÕ TeÏùT\ ®ÚlTm CpûXùVu\ôp 
®X¡d ùLôs[Xôm Guß A±kÕ ùLôiúPu. 
 Bn®u Ø¥®û] ùNôkR AûPVô[eLû[ 
ùY°«PôUp UÚjÕY BWônf£dLôL TVuTÓj§d 
ùLôs[ NmU§d¡ú\u. 
 Sôu GuàûPV ÑV¨û]ÜPàm Utßm ØÝ 
ÑRk§WjÕPàm CkR UÚjÕY BWônf£«p Gu 
ÏZkûRûV úNojÕd ùLôs[ NmU§d¡ú\u.  
 
ùTtú\ôo ûLùVôlTm  
Information to participants 
 
Principal Investigator :-   Dr. SANU SAIN, 
MD Pharmacology Postgraduate 
Chengalpattu medical College 
Chengalpattu. 
Name of the participant:____________________________________________ 
Title  : “A RANDOMISED PROSPECTIVE OPEN LABEL COMPARATIVE STUDY OF 
OLAPATADINE WITH SODIUM CROMOGLYCATE IN ALLERGIC CONJUNCTIVITIS” 
This study is conducted in our institution, Chengalpattu medical College, 
Chengalpattu. 
You are invited to take part in this study. The information in this document is meant 
to help you to decide whether or not to take part. Please feel free to ask if you have 
any queries or concerns. 
You are being asked to participate in this study conducted in the department of 
ophthalmology and department of pharmacology, Chengalpattu Medical College. 
Purpose of research : 
To compare efficacy and tolerability of olapatadine 0.2 % ophthalmic solution once 
daily  with sodium cromoglycate 2% ophthalmic solution four times daily in patients 
with allergic conjunctivitis. 
The study is conducted with permission from the Institutional ethical committee. 
Study design  : Randomized prospective, open labelled comparative study. 
  
STUDY PROCEDURE 
 
The study involves dividing allergic conjunctivitis patients to two groups, after 
initial baseline assessment, one group will receive olopatadine 0.2% ophthalmic 
solution  once daily for six weeks, other group will  receive sodium cromoglycate 2% 
ophthalmic solution four times daily for six weeks. 
Reassessment of patient will be done at 2nd week, 3rd week, 4th week and 
patients will be followed up to 2weeks after study. 
You will be asked to review at regular intervals. At each visit ophthalmologist 
will examine your eyes. 
In addition, if you notice any physical or mental change, you must contact the 
persons listed at the end of the document. 
 You may have to come to hospital for examination and investigations apart 
from your scheduled visits if require 
You must not participate if you are pregnant, breast feeding a child or 
suffering from any serious ocular disease, active ocular infection, dry eyes, underwent 
an ocular surgery in past three months, allergic to study medications, known allergic 
to benzalkonium chloride, not willing to discontinue contact lens, taking oral 
immuno-suppressants, topical steroids, artificial tear drops. 
Benefits of the study : 
The results of the research may provide benefits to the society in terms of 
increase in patient’s compliance to once daily dosage of olopatadine among allergic 
conjunctivitis patients compared to four times daily dosage of sodium cromoglycate. 
 
 
 
 
 
RLYp T¥Ym 
 
ùNeLpThÓ AWÑ ùTôÕ UÚjÕYUû]«p Li £¡fûNl 
©¬®p JqYôûR ®¯ ùYiTPX AZt£ úSôndÏ YZeLlTÓm 
JXlTôh¥¥u ûahúWô Ïú[ôûWÓ, úNô¥Vm ÏúWôúUô 
¡û[dúLÓ B¡V UÚkÕL°u TVuTôÓ Utßm TôÕLôl× 
Ï±jRô] JlÀhÓ BnÜ úUtùLôs[lTÓ¡\Õ. 
 CkR BnÜ AàTYm YônkR UÚjÕYoL°u ER®úVôÓ 
SPjRlTÓ¡\Õ. 
 CmUÚkÕLs Aà§]m TVuTôh¥p Es[ UÚkÕLú[ 
CmUÚkÕL°]ôp ªLlùT¬V A[®p TdL ®û[ÜLs 
HtTP Yônl× CpûX. 
 BWônf£«u úTôÕ JÚ ©¬®]ÚdÏ JXlTôh¥¥u 
ûa¥úWô Ïú[ôûWÓm, Utù\ôÚ ©¬®]ÚdÏ úNô¥Vm 
ÏúWôúUô ¡û[dúLÓm YZeLlTÓm.  Cl©¬®p HúRàm 
Ju±p BWônf£«p TeÏ ùTßTYoLs úNodLlTÓYôoLs. 
 úSôVô°LÞdÏ CmUÚkÕL°u êXm HtTÓm Øuú]t\m 
CWiÓ YôWeLÞdÏ JÚØû\ Li UÚjÕYWôp 
T¬úNô§jÕ A±lTÓm. 
 úSô«u RuûULû[ ùY°«Óm úTôÕ ReL[Õ 
ùTVûWúVô AûPVô[eLû[úVô ùY°«P UôhúPôm 
GuTûRÙm ùR¬®jÕd ùLôs¡ú\u. 
 CkR BWônf£«p TeúLtTÕ EeLÞûPV ®ÚlTj§u 
úT¬p Rôu CÚd¡\Õ.  úUÛm ¿eLs GkúSWØm CkR 
BWônf£«­ÚkÕ ©u YôeLXôm GuTûRÙm ùR¬®jÕd 
ùLôs¡ú\ôm. 
 CkR £\l× T¬úNôRû]L°u Ø¥ÜLû[ BWônf£«u 
úTôÕ ApXÕ BWônf£«u Ø¥®u úTôÕ ReLÞdÏ 
A±®lúTôm GuTûRÙm ùR¬®jÕd ùLôs¡ú\ôm. 
ÏZkûRLÞdLô] RLYp T¥Ym 
 
ùNeLpThÓ AWÑ ùTôÕ UÚjÕYUû]«p Li £¡fûNl ©¬®p 
JqYôûR ®¯ ùYiTPX AZt£ úSôndÏ YZeLlTÓm JXlTôh¥¥u 
ûahúWô Ïú[ôûWÓ, úNô¥Vm ÏúWôúUô ¡û[dúLÓ B¡V 
UÚkÕL°u TVuTôÓ Utßm TôÕLôl× Ï±jRô] JlÀhÓ BnÜ 
úUtùLôs[lTÓ¡\Õ. 
 CkR BnÜ AàTYm YônkR UÚjÕYoL°u ER®úVôÓ 
SPjRlTÓ¡\Õ. 
 CmUÚkÕLs Aà§]m TVuTôh¥p Es[ UÚkÕLú[ 
CmUÚkÕL°]ôp ªLlùT¬V A[®p TdL ®û[ÜLs HtTP 
Yônl× CpûX. 
 BWônf£«u úTôÕ JÚ ©¬®]ÚdÏ JXlTôh¥¥u ûa¥úWô 
Ïú[ôûWÓm, Utù\ôÚ ©¬®]ÚdÏ úNô¥Vm ÏúWôúUô 
¡û[dúLÓm YZeLlTÓm.  Cl©¬®p HúRàm Ju±p 
BWônf£«p TeÏ ùTßTYoLs úNodLlTÓYôoLs. 
 úSôVô°LÞdÏ CmUÚkÕL°u êXm HtTÓm Øuú]t\m 
CWiÓ YôWeLÞdÏ JÚØû\ Li UÚjÕYWôp T¬úNô§jÕ 
A±lTÓm. 
 CkR £\l× T¬úNôRû]L°u Ø¥ÜLû[ BWônf£«u úTôÕ 
ApXÕ BWônf£«u Ø¥®u úTôÕ ReLÞdÏ A±®lúTôm 
GuTûRÙm ùR¬®jÕd ùLôs¡ú\ôm. 
 CkR BWônf£«p EeLs ÏZkûRLÞm TeúLtL SôeLs 
®Úm×¡ú\ôm ARtÏ ReL°u Jl×RûXl ùT\ ®Úm×¡ú\ôm. 
 úSô«u RuûULû[ ùY°«Óm úTôÕ ReL[Õ ÏZkûR«u 
ùTVûWúVô AûPVô[eLû[úVô ùY°«P UôhúPôm 
GuTûRÙm ùR¬®jÕd ùLôs¡ú\u. 
 CkR BWônf£«p EeLs ÏZkûRLs TeúLtTÕ EeLÞûPV 
®ÚlTj§u úT¬p Rôu CÚd¡\Õ.  úUÛm ¿eLs GkúSWØm 
EeLs ÏZkûRLû[ CkR BWônf£«­ÚkÕ ©u YôeLXôm 
GuTûRÙm ùR¬®jÕd ùLôs¡ú\ôm. 
STUDY PROFORMA 
DATE :       Op  no: 
NAME     :     
AGE      : 
SEX      : 
ADDRESS     : 
 
OCCUPATION    : 
PHONE NUMBER    :  
PRESENTING COMPLAINTS  : 
HISTORY OF PRESENTING COMPLAINTS: 
DURATION OF ILLNESS   : 
TREATMENT HISTORY   : 
DIAGNOSIS     : 
RELEAVENT PAST HISTORY:      H/O  BRONCHIAL  ASTHMA  : YES  / NO 
 H/O DRUG ALLERGY: YES / NO 
 FAMILY HISTORY: YES /NO 
 HISTORY OF USE OF CONTACT LENS 
GENERAL EXAMINATION  : 
VITALS     : 
PULSE RATE    : 
BLOOD PRESSURE    : 
RESPIRATORY RATE   : 
SYSTEMIC EXAMINATION  : 
CASE EXAMINATION   : 
LENS      :  
Name the medication given for the patient : 
Olopatadine 0.2% OD               OR               Sodium cromoglycate 2% qid 
SLIT LAMP EXAMINATION  : 
Table I  Efficacy Assessment  
Itch
ing 
Sco
re 0
-3         
Red
nes
s 
Sco
re 0
-3         
Che
mos
is 
Sco
re 0
-3         
Eye
lid 
Swe
llin
g 
Sco
re0-
3         
Wa
teri
ng 
Sco
re 0
-3         
For
eign
 
bod
y 
Sco
re 0
-3         
Pho
top
hob
ia 
Sco
re 0
-3         
Stin
ging
 
Sco
re 0
-3         
Dis
com
fort
 
Sco
re 0
-3         
  Vis
it 1 
2nd  
wk 
3rd  
wk 
4th  w
k 
 
 
Table II  Tolerability Assessment   
 VISIT-1 BASELINE 2
ND WEEK 3rd  WEEK 4TH WEEK 
IOP     
VISUAL  ACUITY     
FUNDUS EXAMINATION     
SLIT LAMP EXAMINATION     
OTHERS     
 
 Follow up:During 6th week 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART  
sl no
: 
Age
 sex 
ITCH
ING 
( 0) 
ITCH
ING(
2) 
Cha
nge
 Fro
m B
asel
ine 
chan
ge fr
om B
L(4-
0) 
ITCH
ING 
(3) 
Itch
ing(
4) 
redn
ess(
0) 
redn
ess(
2) 
chan
ge fr
om b
asel
ine 
redn
ess(
3) 
redn
ess(
4) 
Cha
nge
 from
 bas
eline
 
chem
osis
(0) 
chem
osis
(2) 
chan
ge 2
nd w
eek 
chem
osis
(3) 
chem
osis
(4) 
Cha
nge
 from
 bas
eline
 
eye 
lid e
dem
a(0)
eye 
lid 
edem
a(2) 
chan
ge  f
rom
 bas
eline
 
eye 
lid e
dem
a(3)
 
eyel
id ed
ema
(4) 
chan
ge fr
om b
asel
ine 
wate
ring
(0) 
wate
ring
(2) 
chan
ge fr
om b
asel
ine 
wate
ring
(3) 
wate
ring
(4) 
Cha
nge
 from
 bas
eline
 
fb se
nsat
ion(
0) 
FB S
ensa
tion
(2) 
Cha
nge
 from
 bas
eline
 
fb(3
) 
fb(4
) 
chan
ge fr
om b
asel
ine 
disc
omf
ort(0
) 
disc
omf
ort(2
) 
chan
ge fr
om b
asel
ine 
disc
omf
ort(3
) 
chan
ge a
t 3w
eek 
disc
omf
ort(4
) 
Cha
nge
 from
 bas
eline
 
pho
toph
obia
(0)p
hoto
pho
bia (
2) 
Cha
nge
 from
 bas
eline
 
pho
toph
obia
(3) 
pho
toph
obia
(4) 
Cha
nge
 from
 bas
eline
 
stin
ging
(0)s
ting
ing(
2) 
Cha
nge
 from
 bas
eline
 
sting
ing(
3) 
sting
ing (
4) 
Cha
nge
 from
 bas
eline
 
1 4 M 3 1 2 3 0 0 2 0 2 0 0 2 1 0 1 0 0 1 1 0 1 0 0 1 1 0 1 0 0 1 2 1 1 0 0 2 2 1 1 1 1 0 2 0 0 2 0 0 2 2 0 2 0 0 2 
2 6 F 3 1 2 3 0 0 3 1 2 0 0 3 1 0 1 0 0 1 1 0 1 0 0 1 2 1 1 1 0 2 2 0 2 0 0 2 1 0 1 0 1 0 1 0 0 1 0 0 1 2 0 2 0 0 2 
3 26 M 3 1 2 3 0 0 3 2 1 1 0 3 2 1 1 0 0 2 1 1 0 0 0 1 2 0 2 0 0 2 3 1 2 0 0 3 1 1 0 0 1 0 1 1 0 0 0 0 1 3 1 2 0 0 3 
4 8 F 2 1 1 2 0 0 2 0 2 0 0 2 1 0 1 0 0 1 0 0 0 0 0 0 1 0 1 0 0 1 3 2 1 1 0 3 2 1 1 0 2 0 2 0 0 2 0 0 2 2 0 2 0 0 2 
5 7 M 3 1 2 3 0 0 3 0 3 0 0 3 1 0 1 0 0 1 2 1 1 1 1 1 1 0 1 0 0 1 2 1 1 0 0 2 3 2 1 1 2 0 3 0 0 3 0 0 3 3 0 3 0 0 3 
6 33 M 3 1 2 3 0 0 3 2 1 2 1 2 2 1 1 0 0 2 1 1 0 0 0 1 2 1 1 0 0 2 2 0 2 0 0 2 1 0 1 0 1 0 1 1 0 0 0 0 1 2 0 2 0 0 2 
7 29 M 3 1 2 3 0 0 3 2 1 1 0 3 1 1 0 0 0 1 0 0 0 0 0 0 2 0 2 0 0 2 2 1 1 0 0 2 1 0 1 0 1 0 1 1 0 0 0 0 1 2 0 2 0 0 2 
8 22 F 3 1 2 3 0 0 2 1 1 0 0 2 1 0 1 0 0 1 0 0 0 0 0 0 1 0 1 0 0 1 2 0 2 0 0 2 2 1 1 0 2 0 2 0 0 2 0 0 2 3 1 2 1 0 3 
9 6 F 2 0 2 2 0 0 2 1 1 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 1 0 2 2 1 1 0 0 2 1 0 1 0 1 0 1 0 0 1 0 0 1 3 0 3 0 0 3 
10 6 F 2 1 1 2 0 0 2 1 1 0 0 2 1 0 1 0 0 1 2 1 1 1 0 2 2 1 1 1 0 2 3 1 2 1 0 3 3 2 1 1 2 0 3 0 0 3 0 0 3 3 0 3 0 0 3 
11 7 M 2 0 2 2 0 0 2 1 1 0 0 2 0 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 0 0 2 1 1 0 0 2 3 2 1 1 2 0 3 0 0 3 0 0 3 2 0 2 0 0 2 
12 9 M 2 0 2 2 0 0 3 0 3 0 0 3 1 0 1 0 0 1 0 0 0 0 0 0 1 0 1 0 0 1 3 0 3 0 0 3 2 1 1 0 2 0 2 0 0 2 0 0 2 2 0 2 0 0 2 
13 11 F 2 0 2 2 0 0 2 0 2 0 0 2 2 0 2 0 0 2 0 0 0 0 0 0 1 0 1 0 0 1 2 0 2 0 0 2 1 0 1 0 1 0 1 0 0 1 0 0 1 3 0 3 0 0 3 
14 22 M 3 2 1 3 1 0 2 1 1 1 1 1 1 0 1 0 0 1 1 0 1 0 0 1 1 0 1 0 0 1 2 1 1 0 0 2 1 0 1 0 1 0 1 1 0 0 0 0 1 2 0 2 0 0 2 
15 11 M 3 1 2 3 0 0 3 2 1 1 0 3 1 1 0 0 0 1 1 1 0 0 0 1 1 0 1 0 0 1 3 0 3 0 0 3 1 0 1 0 1 0 1 1 0 0 0 0 1 2 0 2 0 0 2 
16 32 F 3 1 2 3 0 0 3 2 1 1 1 2 2 1 1 1 0 2 1 0 1 0 0 1 1 0 1 0 0 1 2 0 2 0 0 2 0 0 0 0 0 0 0 1 0 -1 0 0 0 2 1 1 0 0 2 
17 12 F 3 2 1 3 1 0 3 0 3 0 0 3 1 0 1 0 0 1 0 0 0 0 0 0 2 1 1 1 1 1 3 2 1 1 0 3 0 0 0 0 0 0 0 1 0 -1 0 0 0 2 0 2 1 1 1 
18 13 M 2 1 1 2 0 0 2 1 1 0 0 2 1 0 1 0 0 1 0 0 0 0 0 0 1 0 1 0 0 1 2 0 2 0 0 2 2 1 1 1 1 0 2 0 0 2 0 0 2 2 0 2 0 0 2 
19 5 M 2 0 2 2 0 0 2 0 2 0 0 2 1 0 1 0 0 1 1 0 1 0 0 1 1 1 0 0 0 1 2 1 1 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 3 1 2 0 0 3 
20 5 F 2 0 2 2 0 0 3 1 2 0 0 3 0 0 0 0 0 0 1 1 0 1 0 1 0 0 0 0 0 0 2 1 1 0 0 2 2 1 1 1 1 1 1 0 0 1 0 0 1 3 0 3 0 0 3 
21 8 F 2 1 1 2 0 0 2 0 2 0 0 2 0 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 0 0 2 0 2 0 0 2 1 1 0 0 1 0 1 0 0 1 0 0 1 2 0 2 0 0 2 
22 4 M 3 2 1 2 1 1 3 1 2 0 0 3 1 0 1 1 0 1 0 0 0 0 0 0 1 0 1 0 0 1 3 0 3 0 0 3 3 2 1 1 2 1 2 1 0 1 0 0 2 2 0 2 0 0 2 
23 6 F 3 2 1 2 1 1 3 1 2 0 0 3 2 1 1 1 0 2 1 1 0 1 0 1 2 0 2 0 0 2 2 1 1 0 0 2 1 0 1 0 1 0 1 1 1 0 0 0 1 3 0 3 0 0 3 
24 55 M 3 1 2 3 0 0 3 2 1 1 0 3 1 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 1 2 0 2 0 0 2 1 0 1 0 1 0 1 1 0 0 0 0 1 1 1 0 0 0 1 
25 17 M 2 0 2 2 0 0 2 0 2 0 0 2 1 0 1 0 0 1 0 0 0 0 0 0 1 1 0 1 0 1 2 0 2 0 0 2 2 0 2 0 2 0 2 0 0 2 0 0 2 2 0 2 0 0 2 
26 24 F 2 1 1 2 0 0 2 1 1 1 0 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 3 1 2 0 0 3 3 2 1 1 2 0 3 0 0 3 0 0 3 2 0 2 1 0 2 
27 6 M 3 1 2 3 0 0 2 1 1 0 0 2 1 0 1 0 0 1 1 0 1 0 0 1 0 0 0 0 0 0 3 0 3 0 0 3 2 2 0 1 1 0 2 1 0 1 0 0 2 2 1 1 0 0 2 
28 7 M 3 0 3 3 0 0 3 1 2 1 0 3 2 0 2 0 0 2 1 1 0 0 0 1 2 1 1 0 0 2 2 1 1 0 0 2 1 0 1 0 1 0 1 1 0 0 0 0 1 2 1 1 0 0 2 
29 22 F 2 1 1 2 0 0 2 0 2 0 0 2 1 0 1 0 0 1 0 0 0 0 0 0 1 0 1 0 0 1 2 0 2 0 0 2 2 1 1 1 1 1 1 0 0 1 0 0 1 2 0 2 0 0 2 
30 15 F 2 1 1 2 0 0 2 0 2 0 0 2 1 0 1 0 0 1 0 0 0 0 0 0 1 0 1 0 0 1 3 1 2 0 0 3 1 0 1 0 1 0 1 0 0 1 0 0 1 2 0 2 1 0 2 
31 14 F 3 1 2 3 0 0 2 1 1 1 0 2 1 0 1 0 0 1 1 1 0 0 0 1 1 0 1 0 0 1 3 0 3 0 0 3 1 0 1 0 1 0 1 1 0 0 0 0 1 3 0 3 0 0 3 
32 44 M 3 1 2 3 1 1 2 1 1 0 0 1 0 1 0 0 1 1 0 1 0 0 1 1 0 1 0 0 1 2 0 2 0 0 2 2 1 1 0 2 0 2 1 0 1 0 0 2 3 0 3 0 0 3 
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33 23 F 3 1 2 3 0 0 3 2 1 1 0 3 2 1 1 1 0 2 1 0 1 0 0 1 2 1 1 0 0 2 2 1 1 0 0 2 1 0 1 0 1 0 1 1 0 0 0 0 1 2 1 1 0 0 2 
34 12 M 3 0 3 3 0 0 3 0 3 0 0 3 0 0 0 0 0 0 2 0 2 0 0 2 1 0 1 0 0 1 2 0 2 0 0 2 3 1 2 1 2 0 3 0 0 3 0 0 3 2 0 2 0 0 2 
35 13 M 3 0 3 3 0 0 2 0 2 0 0 2 0 0 0 0 0 0 1 1 0 0 0 1 2 1 1 0 0 2 2 0 2 0 0 2 2 1 1 0 2 0 2 0 0 2 0 0 2 2 0 2 0 0 2 
36 5 F 2 0 2 2 0 0 3 0 3 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 2 0 2 0 0 2 1 0 1 0 1 0 1 0 0 1 0 0 1 3 0 3 0 0 3 
37 4 F 2 1 1 2 0 0 3 1 2 1 0 3 1 0 1 0 0 1 1 0 1 0 0 1 1 1 0 0 0 1 2 0 2 0 0 2 3 2 1 1 2 0 3 0 0 3 0 0 3 2 0 2 0 0 2 
38 4 M 2 0 2 2 0 0 2 0 2 0 0 2 0 0 0 0 0 0 1 0 1 0 0 1 1 0 1 0 0 1 2 0 2 0 0 2 1 0 1 0 1 0 1 0 0 1 0 0 1 2 0 2 0 0 2 
39 7 M 2 0 2 2 0 0 2 1 1 1 0 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 2 0 2 0 0 2 3 1 2 1 2 1 2 0 0 2 0 0 2 2 0 2 0 0 2 
40 33 F 3 1 2 3 0 0 3 2 1 1 1 2 1 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 1 3 1 2 0 0 3 2 1 1 1 1 0 2 1 0 1 0 0 2 2 0 2 0 0 2 
41 23 M 3 2 1 3 1 1 3 2 1 1 1 2 1 1 0 0 0 1 1 0 1 0 0 1 2 1 1 0 0 2 3 0 3 0 0 3 2 0 2 0 2 0 2 1 0 1 0 0 2 3 0 3 0 0 3 
42 13 M 2 1 1 3 1 0 2 0 2 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 0 0 2 3 1 2 0 0 3 1 0 1 0 1 0 1 0 0 1 0 0 1 3 0 3 0 0 3 
43 12 M 2 1 1 2 0 0 2 1 1 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 0 0 2 2 0 2 0 0 2 3 1 2 1 2 0 3 0 0 3 0 0 3 3 0 3 0 0 3 
44 24 M 3 1 2 3 0 0 3 1 2 0 0 3 1 0 1 0 0 1 1 0 1 0 0 1 1 0 1 0 0 1 3 1 2 0 0 3 1 0 1 0 1 0 1 1 0 0 0 0 1 3 0 3 0 0 3 
45 22 F 3 1 2 3 0 0 2 0 2 0 0 2 1 0 1 0 0 1 2 1 1 0 0 2 2 1 1 0 0 2 2 1 1 0 0 2 1 0 1 0 1 0 1 1 0 0 0 0 1 2 0 2 0 0 2 
46 32 F 3 2 1 3 1 0 2 1 1 0 0 2 1 1 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 1 2 0 2 0 0 2 2 1 1 0 2 0 2 1 0 1 0 0 2 2 0 2 0 0 2 
47 31 M 3 1 2 3 0 0 3 2 1 1 1 2 1 1 0 0 0 1 0 0 0 0 0 0 2 1 1 0 0 2 2 1 1 0 0 2 3 2 1 0 3 0 3 1 0 2 0 0 3 2 1 1 0 0 2 
48 4 F 2 1 1 2 0 0 3 1 2 1 1 2 0 0 0 0 0 0 2 1 1 1 0 2 1 0 1 0 0 1 2 0 2 0 0 2 3 2 1 1 2 0 3 0 0 3 0 0 3 2 0 2 0 0 2 
49 9 M 3 0 3 3 0 0 3 1 2 1 0 3 0 0 0 0 0 0 0 0 0 0 0 0 3 1 2 1 0 3 2 1 1 0 0 2 3 1 2 0 3 0 3 0 0 3 0 0 3 2 0 2 0 0 2 
50 6 M 2 0 2 2 0 0 2 1 1 0 0 2 0 0 0 0 0 0 1 1 0 0 0 1 1 0 1 0 0 1 2 0 2 0 0 2 1 0 1 0 1 0 1 0 0 1 0 0 1 2 0 2 0 0 2 
51 19 M 3 1 2 3 1 0 2 1 1 0 0 2 1 0 1 0 0 1 1 0 1 0 0 1 1 0 1 0 0 1 2 1 1 0 0 2 2 0 2 0 2 0 2 1 0 1 0 0 2 2 0 2 0 0 2 
52 22 M 3 1 2 3 0 0 3 1 2 1 0 3 2 0 2 0 0 2 0 0 0 0 0 0 2 0 2 0 0 2 2 0 2 0 0 2 1 0 1 0 1 0 1 1 1 0 0 0 1 2 0 2 0 0 2 
53 36 F 3 2 1 2 1 1 3 1 2 0 0 3 2 0 2 0 0 2 1 0 1 0 0 1 2 0 2 0 0 2 2 1 1 0 0 2 1 0 1 0 1 0 1 1 0 0 0 0 1 2 0 2 0 0 2 
54 39 M 3 1 2 3 0 0 3 2 1 1 1 2 2 1 1 1 0 2 1 0 1 0 0 1 2 0 2 0 0 2 2 0 2 0 0 2 2 0 2 0 2 0 2 1 0 1 0 0 2 2 0 2 0 0 2 
55 27 M 3 2 1 3 0 0 3 2 1 1 0 3 1 1 0 1 0 1 1 1 0 1 0 1 1 0 1 0 0 1 2 1 1 0 0 2 1 0 1 0 1 0 1 1 0 0 0 0 1 2 0 2 0 0 2 
56 4 M 3 1 2 3 0 0 2 0 2 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 2 0 2 0 0 2 3 1 2 1 2 0 3 0 0 3 0 0 3 2 0 2 0 0 2 
57 4 M 2 1 1 1 1 1 3 2 1 0 0 3 0 0 0 0 0 0 1 0 1 0 0 1 1 0 1 0 0 1 2 1 1 0 0 2 1 0 1 0 1 0 1 0 0 1 0 0 1 3 0 3 0 0 3 
58 7 M 2 1 1 2 0 0 2 1 1 1 0 2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 2 0 2 0 0 2 1 0 1 0 1 0 1 0 0 1 0 0 1 2 0 2 0 0 2 
59 10 M 3 1 2 3 0 0 3 0 3 0 0 3 1 0 1 0 0 1 2 1 1 0 0 2 1 0 1 0 0 1 3 0 3 0 0 3 2 1 1 0 2 0 2 1 0 1 0 0 2 2 0 2 0 0 2   
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1 4 F 2 0 2 0 2 0 2 3 2 1 1 2 0 3 1 0 1 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 1 1 0 2 0 2 2 1 1 1 1 0 2 1 0 1 0 1 0 1 2 1 1 11 1 1 
2 5 M 3 2 1 1 2 0 3 2 2 0 1 1 1 1 1 1 0 1 0 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 0 0 0 0 0 0 0 2 0 2 02 0 2 
3 6 F 2 1 1 1 1 0 2 3 1 2 1 2 0 3 1 0 1 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 0 2 0 2 0 2 2 2 0 1 1 1 1 1 0 1 0 1 0 1 3 1 2 03 0 3 
4 5 M 3 2 1 1 2 0 3 2 1 1 0 2 0 2 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 1 1 0 2 1 1 1 0 1 0 1 0 1 0 0 0 0 0 0 0 3 0 3 03 0 3 
5 11 M 2 2 0 1 1 0 2 2 2 0 1 1 0 2 1 1 0 0 1 0 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 0 2 0 2 0 2 2 1 1 0 2 0 2 0 0 0 0 0 0 0 3 0 3 03 0 3 
6 13 M 3 1 2 1 2 0 3 3 1 2 1 2 0 3 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 0 2 0 2 0 2 2 1 1 0 2 0 2 1 1 0 0 1 0 1 3 0 3 03 0 3 
7 6 F 3 2 1 1 2 0 3 3 1 2 1 2 0 3 1 1 0 0 1 0 1 1 0 1 0 1 0 1 2 0 2 0 2 0 2 1 0 1 0 1 0 1 1 0 1 0 1 0 1 0 0 0 0 0 0 0 2 0 2 02 0 2 
8 4 F 3 1 2 0 3 0 3 2 2 0 1 1 1 1 1 1 0 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 0 0 0 0 0 0 0 2 0 2 02 0 2 
9 33 M 3 1 2 1 2 1 2 2 1 1 0 2 0 2 1 0 1 0 1 0 1 1 1 0 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 1 1 0 2 0 2 1 0 1 0 1 0 1 2 0 2 02 0 2 
10 23 F 3 1 2 0 3 0 3 2 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 0 2 0 2 1 0 1 0 1 0 1 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 0 1 01 0 1 
11 11 M 2 1 1 0 2 0 2 3 2 1 2 1 1 2 2 1 1 0 2 0 2 1 1 0 1 0 0 1 2 1 1 0 2 0 2 1 0 1 0 1 0 1 2 1 1 0 2 0 2 1 1 0 0 1 0 1 1 0 1 01 0 1 
12 21 F 2 0 2 0 2 0 2 3 1 2 0 3 0 3 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 0 2 0 2 0 2 2 0 2 0 2 0 2 0 0 0 0 0 0 0 1 0 1 01 0 1 
13 14 M 2 1 1 1 1 0 2 3 1 2 0 3 0 3 2 1 1 1 1 0 2 2 1 1 0 2 0 2 1 0 1 0 1 0 1 2 1 1 1 1 0 2 2 1 1 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
14 4 M 2 1 1 1 1 0 2 2 2 0 1 1 0 2 1 1 0 0 1 0 1 1 1 0 0 1 0 1 2 1 1 1 1 0 2 1 1 0 0 1 0 1 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 1 1 02 0 2 
15 5 M 3 1 2 0 3 0 3 2 1 1 1 1 0 2 2 1 1 0 2 0 2 1 0 1 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 3 1 2 0 3 0 3 1 0 1 0 1 0 1 1 0 1 01 0 1 
16 6 M 2 2 0 1 1 0 2 2 1 1 1 1 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 0 2 0 2 2 1 1 1 1 1 1 2 1 1 0 2 0 2 0 0 0 0 0 0 0 3 2 1 12 0 3 
17 9 M 2 1 1 1 1 0 2 3 2 1 2 1 1 2 2 1 1 1 1 1 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 1 1 0 2 0 2 0 0 0 0 0 0 0 3 1 2 03 0 3 
18 12 M 2 1 1 0 2 0 2 3 2 1 1 2 1 2 2 1 1 1 1 1 1 2 1 1 0 2 0 2 2 1 1 0 2 0 2 2 1 1 0 2 0 2 2 1 1 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
19 11 M 2 1 1 1 1 1 1 1 1 0 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 1 1 1 1 1 1 2 1 1 0 2 0 2 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
20 43 F 2 0 2 0 2 0 2 2 1 1 0 2 0 2 0 0 0 0 0 0 0 1 0 1 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 3 0 3 0 3 0 3 1 1 0 1 0 0 1 2 0 2 02 0 2 
21 12 F 2 0 2 1 1 0 2 2 1 1 0 2 0 2 0 0 0 0 0 0 0 1 1 0 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 0 2 0 2 0 2 1 0 1 0 1 0 1 2 0 2 02 0 2 
22 4 F 3 2 1 0 3 0 3 3 1 2 0 3 0 3 1 1 0 1 0 0 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 1 1 0 2 0 2 3 0 3 0 3 0 3 0 0 0 0 0 0 0 1 0 1 01 0 1 
23 7 M 3 2 1 2 1 2 1 3 1 2 0 3 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 1 1 0 2 0 2 2 1 1 0 2 0 2 0 0 0 0 0 0 0 2 1 1 11 0 2 
24 8 F 3 1 2 0 3 0 3 3 2 1 1 2 1 2 1 0 1 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 1 1 0 0 1 0 1 2 1 1 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
25 7 M 2 2 0 1 1 0 2 2 1 1 1 1 1 1 0 0 0 0 0 0 0 1 1 0 0 1 0 1 1 0 1 0 1 0 1 3 2 1 2 1 0 3 2 1 1 0 2 0 2 0 0 0 0 0 0 0 3 1 2 12 1 2 
26 9 F 2 2 0 0 2 0 2 2 1 1 1 1 1 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 1 1 0 2 0 2 1 1 0 0 1 0 1 3 0 3 0 3 0 3 1 0 1 0 1 0 1 3 1 2 03 0 3 
27 11 M 2 1 1 0 2 0 2 2 1 1 1 1 0 2 0 0 0 0 0 0 0 1 0 1 0 1 0 1 1 1 0 0 1 0 1 1 1 0 1 0 0 1 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
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28 32 M 3 1 2 0 3 0 3 2 1 1 1 1 1 1 0 0 0 0 0 0 0 1 1 0 0 1 0 1 1 0 1 0 1 0 1 1 1 0 1 0 0 1 3 0 3 0 3 0 3 1 0 1 0 1 0 1 2 0 2 02 0 2 
29 33 M 3 2 1 1 2 1 2 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 0 2 0 2 0 2 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
30 42 M 3 2 1 1 2 1 2 3 1 2 1 2 0 3 1 1 0 1 0 0 1 2 1 1 1 1 1 1 2 1 1 0 2 0 2 2 0 2 0 2 0 2 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
31 23 F 3 2 1 1 2 1 2 3 2 1 1 2 1 2 1 0 1 0 1 0 1 0 0 0 0 0 0 0 2 1 1 1 1 1 1 1 0 1 0 1 0 1 2 1 1 0 2 0 2 0 0 0 0 0 0 0 3 1 2 03 0 3 
32 35 F 2 2 0 1 1 0 2 3 1 2 1 2 1 2 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 1 1 0 2 0 2 1 0 1 0 1 0 1 3 1 2 03 0 3 
33 36 M 3 1 2 1 2 0 3 2 0 2 0 2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 0 2 0 2 2 2 0 1 1 0 2 3 1 2 1 2 0 3 1 0 1 0 1 0 1 2 0 2 02 0 2 
34 11 M 2 2 0 1 1 0 2 3 2 1 1 2 0 3 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 1 0 1 0 1 0 1 3 0 3 0 3 0 3 1 0 1 0 1 0 1 2 0 2 02 0 2 
35 4 F 3 2 1 1 2 0 3 2 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
36 8 F 3 1 2 1 2 1 2 2 1 1 0 2 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 0 2 0 2 2 1 1 0 2 0 2 2 1 1 0 2 0 2 1 0 1 0 1 0 1 1 0 1 01 0 1 
37 5 M 3 2 1 1 2 1 2 3 2 1 1 2 1 2 1 1 0 1 0 0 1 0 0 0 0 0 0 0 2 1 1 0 2 0 2 1 1 0 0 1 0 1 2 1 1 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
38 43 F 2 0 2 0 2 0 2 3 1 2 0 3 0 3 1 0 1 0 1 0 1 1 1 0 1 0 0 1 2 1 1 0 2 0 2 2 0 2 0 2 0 2 3 0 3 0 3 0 3 0 0 0 0 0 0 0 3 0 3 03 0 3 
39 21 M 2 0 2 0 2 0 2 2 1 1 1 1 1 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 1 1 1 1 0 2 3 0 3 0 3 0 3 0 0 0 0 0 0 0 3 0 3 03 0 3 
40 32 M 3 1 2 0 3 0 3 2 1 1 0 2 0 2 0 0 0 0 0 0 0 1 1 0 0 1 0 1 2 0 2 0 2 0 2 2 1 1 0 2 0 2 1 0 1 0 1 0 1 0 0 0 0 0 0 0 3 1 2 12 0 3 
41 6 F 2 1 1 0 2 0 2 2 2 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 0 2 0 2 0 2 0 0 0 0 0 0 0 3 0 3 03 0 3 
42 5 F 3 2 1 1 2 1 2 2 2 0 0 2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 0 2 0 2 1 0 1 0 1 0 1 2 0 2 0 2 0 2 1 0 1 0 1 0 1 3 1 2 12 1 2 
43 22 M 3 2 1 1 2 1 2 3 2 1 0 3 0 3 1 1 0 1 0 0 1 2 1 1 1 1 1 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
44 23 M 2 0 2 0 2 0 2 3 1 2 1 2 1 2 1 0 1 0 1 0 1 0 0 0 0 0 0 0 2 0 2 0 2 0 2 2 2 0 1 1 1 1 3 0 3 0 3 0 3 1 1 0 0 1 0 1 2 0 2 02 0 2 
45 34 M 2 0 2 0 2 0 2 2 1 1 0 2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 1 0 2 0 2 2 1 1 1 1 0 2 2 0 2 0 2 0 2 1 0 1 0 1 0 1 3 0 3 12 0 3 
46 32 M 2 0 2 0 2 0 2 3 2 1 1 2 1 2 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 1 1 1 1 0 2 3 0 3 0 3 0 3 0 0 0 0 0 0 0 2 0 2 02 0 2 
47 6 M 2 0 2 0 2 0 2 2 1 1 0 2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 1 1 1 1 0 2 2 0 2 1 1 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
48 7 F 3 1 2 1 2 0 3 3 1 2 1 2 1 2 1 1 0 0 1 0 1 1 0 1 0 1 0 1 2 0 2 0 2 0 2 2 1 1 0 2 0 2 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
49 6 F 2 0 2 0 2 0 2 2 1 1 1 1 1 1 0 0 0 0 0 0 0 1 1 0 0 1 0 1 2 1 1 0 2 0 2 2 1 1 0 2 0 2 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
50 7 M 1 0 1 1 0 1 0 3 1 2 1 2 1 2 1 1 0 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 1 1 1 1 0 2 2 0 2 0 2 0 2 0 0 0 0 0 0 0 1 0 1 01 0 1 
51 8 M 3 1 2 0 3 0 3 2 1 1 1 1 1 1 1 1 0 0 1 0 1 1 1 0 1 0 1 0 2 1 1 0 2 0 2 2 1 1 0 2 0 2 2 0 2 0 2 0 2 1 1 0 0 1 0 1 2 0 2 02 0 2 
52 4 M 3 2 1 1 2 1 2 2 0 2 0 2 0 2 1 0 1 0 1 0 1 1 0 1 0 1 0 1 0 0 0 0 0 0 0 2 1 1 1 1 1 1 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
53 6 M 2 1 1 1 1 0 2 2 1 1 0 2 0 2 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 1 1 1 1 1 1 1 0 1 0 1 0 1 0 0 0 0 0 0 0 2 0 2 02 0 2 
54 23 M 3 2 1 1 2 1 2 2 1 1 0 2 0 2 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 1 1 1 1 0 2 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
55 27 F 2 0 2 0 2 0 2 2 1 1 0 2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 2 2 0 0 2 0 2 2 1 1 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
56 8 M 2 0 2 1 1 1 1 3 2 1 2 1 2 1 1 1 0 0 1 0 1 1 1 0 1 0 1 0 1 0 1 0 1 0 1 2 1 1 1 1 0 2 2 0 2 0 2 0 2 0 0 0 0 0 0 0 2 0 2 02 0 2 
57 23 M 3 0 3 0 3 0 3 2 1 1 1 1 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 1 1 0 1 0 1 0 1 2 0 2 0 2 0 2 0 0 0 0 0 0 0 1 0 1 10 0 1 
58 34 F 2 0 2 0 2 0 2 3 1 2 0 3 0 3 1 0 1 0 1 0 1 1 1 0 0 1 0 1 1 0 1 0 1 0 1 1 0 1 0 1 0 1 3 0 3 0 3 0 3 1 0 1 0 1 0 1 1 0 1 01 0 1 
